Skip to main content
World Journal of Gastroenterology logoLink to World Journal of Gastroenterology
. 2011 Jun 14;17(22):2748–2773. doi: 10.3748/wjg.v17.i22.

miRNA studies in in vitro and in vivo activated hepatic stellate cells

Gunter Maubach 1,2,3, Michelle Chin Chia Lim 1,2,3, Jinmiao Chen 1,2,3, Henry Yang 1,2,3, Lang Zhuo 1,2,3
PMCID: PMC3122263  PMID: 21734783

Abstract

AIM: To understand which and how different miRNAs are implicated in the process of hepatic stellate cell (HSC) activation.

METHODS: We used microarrays to examine the differential expression of miRNAs during in vitro activation of primary HSCs (pHSCs). The transcriptome changes upon stable transfection of rno-miR-146a into an HSC cell line were studied using cDNA microarrays. Selected differentially regulated miRNAs were investigated by quantitative real-time polymerase chain reaction during in vivo HSC activation. The effect of miRNA mimics and inhibitor on the in vitro activation of pHSCs was also evaluated.

RESULTS: We found that 16 miRNAs were upregulated and 26 were downregulated significantly in 10-d in vitro activated pHSCs in comparison to quiescent pHSCs. Overexpression of rno-miR-146a was characterized by marked upregulation of tissue inhibitor of metalloproteinase-3, which is implicated in the regulation of tumor necrosis factor-α activity. Differences in the regulation of selected miRNAs were observed comparing in vitro and in vivo HSC activation. Treatment with miR-26a and 29a mimics, and miR-214 inhibitor during in vitro activation of pHSCs induced significant downregulation of collagen type I transcription.

CONCLUSION: Our results emphasize the different regulation of miRNAs in in vitro and in vivo activated pHSCs. We also showed that miR-26a, 29a and 214 are involved in the regulation of collagen type I mRNA.

Keywords: Hepatic stellate cells, miRNA, miR-146a, Nuclear factor-κB

INTRODUCTION

Liver fibrosis, characterized by an overproduction of extracellular matrix (ECM), is a common outcome of different chronic liver diseases[1]. Hepatic stellate cells (HSCs) are one of the major cell types responsible for the production of ECM molecules like collagens, laminin, proteoglycans and fibronectin[2]. The production of different ECM molecules is increased upon transdifferentiation (activation) of HSCs from a quiescent to an activated myofibroblast-like state[3,4]. Consequently, the regulation of the complex process of HSC activation is of great interest to the research community. Understanding this process should lead to the discovery of therapeutic strategies for liver fibrosis. Due to the complexity of the activation of HSCs, the number of regulatory steps is expected to be overwhelming[5], and requires addressing many different targets at the same time, either with different compounds or with one compound that is able to work on many different targets.

miRNAs are small approximately 23-nt non-coding RNAs, which are able to regulate hundreds of different proteins. The versatility of miRNAs is attributed to the imperfect binding (seed region) to the 3’-UTR of mRNAs, which results in, contrary to siRNA, many binding partners. The regulation by miRNAs is also different to siRNAs because it leads to a translational repression and/or mRNA destabilization[6,7]. That miRNAs fulfill regulatory functions has been established by their involvement in many different processes and diseases[8,9]. Therefore, it is tempting to use these molecules in order to treat liver fibrosis; a condition that is caused by a deregulation of biological processes. To succeed in this attempt, we need to identify the miRNAs, which are differentially regulated in the normal and diseased liver, and more specifically in the HSCs; one cell type that is responsible for the fibrotic process.

The purpose of this study was to identify differentially regulated miRNAs in in vitro activated HSCs, in order to study them in an in vivo animal model, and finally, to determine their role in the activation process.

MATERIALS AND METHODS

Isolation of rat primary HSCs and cell culture conditions

Wistar rats were used to isolate primary HSCs (pHSCs) according to a published pronase/collagenase in situ perfusion protocol[10]. The isolation protocol was approved by the Institutional Animal Care and Use Committee under #080389. For in vitro activation, the cells were seeded into 75-cm2 culture flasks and harvested after 3, 5, 7 or 10 d. Primary cells and the HSC-2 cell line were cultured in high glucose Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10% fetal bovine serum, 100 U/mL penicillin and 100 μg/mL streptomycin at 37°C in a 5% CO2 humidified incubator.

HSC-2 is a spontaneous immortalized cell line derived from the pHSCs of a male Wistar rat. The primary cells were passaged several times before clonal selection by limiting dilution[11].

The purity of pHSCs from rats on normal and choline-deficient ethionine supplemented (CDE) diet was assessed using vitamin A autofluorescence or real-time polymerase chain reaction (PCR), respectively (Figure 1A). All cell culture reagents were purchased from Invitrogen (Carlsbad, CA, USA).

Figure 1.

Figure 1

Primary hepatic stellate cells and over-expression of miR-146a in hepatic stellate cell-2 cell line. A: Bright-field image of 1 d cultivated primary hepatic stellate cells and the corresponding vitamin A autofluorescence image are shown. Scale bar represents 100 μm. Real-time polymerase chain reaction (PCR) for in vivo activated hepatic stellate cells from rats on normal (n = 2) and choline-deficient ethionine supplemented (CDE) diet (n = 4). The mean ± SE for each diet model is shown; B: A representative image for the over-expression of miR-146a as visualized by the reporter GFP is shown. Real-time PCR for three independent clones confirmed the expression of miR-146a. The data represent the mean ± SE of triplicate reactions. SMAA: Smooth muscle α-actin.

In vivo activation of rat HSCs

Six- to eight-week-old male Wistar rats were fed the CDE diet (CDE model) (MP Biomedicals, Solon, OH, USA, #0296021410) for 4 wk (Figure 2). Livers were isolated, perfused with PBS and fixed in neutralized formalin (paraffin embedding) or in vivo activated pHSCs were isolated.

Figure 2.

Figure 2

Histological and immunohistochemical analysis of livers from rats receiving choline-deficient ethionine supplemented diet for 4 wk. A: HE staining shows the structural changes between control and choline-deficient ethionine supplemented (CDE) diet livers. No severe steatosis is observed; B: The Sirius Red staining depicts the deposition of collagen around the portal area and the whole liver; C: The increase in smooth muscle α-actin (SMAA) staining reflects the increasing number of myofibroblasts seen in patches throughout the liver. Scale bar represents 200 μm; D: The Western blotting data confirm the increase in SMAA and ColI.

Isolation of miRNA for microarray and analysis

miRNA was extracted from quiescent (freshly isolated) and 10-d in vitro-activated pHSCs using the PureLink purification kit (K1570-01; Invitrogen). The miRNA microarray (NCode Multi-Species miRNA microarray V2) was performed according to the manufacturer’s manual (MIRLS-20; Invitrogen). For each experiment, a dye swap was performed. The arrays were scanned using a GenePix 4200AL array scanner. The raw datasets were deposited under #GSE19463 at the Gene Expression Omnibus (GEO) repository[12]. For two-color miRNA arrays, averaging of dye-swapped arrays was performed to minimize the dye effects prior to normalization using the Cross-Correlation method[13]. The targets of differentially regulated miRNAs (Table 1) were predicted by three different methods, TargetScan 5.1[14], mirBASE target[15], and miRNA Viewer[16] using default parameters. Targets predicted by at least two tools were selected and grouped into upregulated and downregulated miRNAs, respectively. These two groups of targets were subjected to pathway analysis using Ingenuity Pathway Analysis (Ingenuity Systems, Redwood City, CA, USA). A ratio was calculated whereby the number of predicted targets in a given pathway was divided by the total number of molecules in that pathway. The Fisher’s exact test was used by the software to calculate a P value. This P value represented the probability that the association between the predicted targets and the pathway could not be explained by chance alone. The P value cutoff was set at P ≤ 0.001. The x axis was the negative logarithm of P value with a base of 10 (-log10 P value).

Table 1.

Differentially regulated miRNAs as identified by miRNA microarray

miRNA name Fold change P value
Upregulated compared to day 0
rno-let-7b 4.70 0.0242
rno-let-7c 3.75 0.0236
rno-let-7e 2.77 0.0340
rno-miR-125b 11.98 0.0113
rno-miR-132 1.97 0.0184
rno-miR-143 17.05 0.0014
rno-miR-145 2.29 0.0483
rno-miR-152 3.01 0.0255
rno-miR-199a 3.46 0.0415
rno-miR-21 5.73 0.0142
rno-miR-210 2.34 0.0186
rno-miR-214 18.44 0.0011
rno-miR-22 3.11 0.0392
rno-miR-221 10.09 0.0007
rno-miR-222 2.67 0.0317
rno-miR-31 8.91 0.0013
Downregulated compared to day 0
rno-let-7f -2.17 0.0327
rno-miR-10a -3.53 0.0417
rno-miR-122a -349.63 0.00002
rno-miR-125a -2.36 0.0474
rno-miR-126 -170.32 0.0003
rno-miR-146a -16.83 0.0352
rno-miR-150 -9.81 0.0325
rno-miR-151* -3.72 0.0345
rno-miR-161 -4.38 0.0366
rno-miR-181a1 -4.50 0.0346
rno-miR-192 -6.08 0.0206
rno-miR-194 -6.08 0.0168
rno-miR-195 -14.50 0.0130
rno-miR-207 -1.93 0.0449
rno-miR-26a -5.17 0.0163
rno-miR-26b -4.81 0.0300
rno-miR-296 -1.93 0.0292
rno-miR-29a1 -2.38 0.0644
rno-miR-30a-5p -5.35 0.0327
rno-miR-30b -10.51 0.0075
rno-miR-30c -9.69 0.0138
rno-miR-30d -8.68 0.0093
rno-miR-335 -3.74 0.0500
rno-miR-422b1 -8.49 0.0455
rno-miR-483 -2.49 0.0451
rno-miR-99a -2.97 0.0383
1

Data from two experiments.

Real-time PCR

The verification of the microarray data and subsequent miRNA assessments were performed for let-7b, let-7c, miR-16, 26a, 29a, 31, 125b, 143, 146a, 150 and 214 by using the respective Taqman MicroRNA assays (P/N 4427975, Applied Biosystems, Foster City, CA, USA). The U6 snRNA assay (ID 001973) served as a normalization control. Total RNA was isolated using the NucleoSpin RNAII kit (Macherey-Nagel, Germany). Total RNA and miRNA were isolated using the same kit but with a small modification. Briefly, the cell lysate was adjusted to contain 35% ethanol and passed through the RNAII column to bind the total RNA. The ethanol concentration of the flow through was then adjusted to > 70% and passed through the same column in order to bind the miRNA. The Cells-to-Ct kit (Invitrogen, P/N 4391848) was used for some experiments to quantify the miRNA expression with the respective miRNA assays. The reverse transcription and real-time PCR were performed according to the assays protocol using the ABI 7500 Fast Real Time PCR System (Applied Biosystems). Taqman assays used were smooth muscle α-actin (SMAA) (Rn01759928_g1), Col1a1 (Rn01463849_g1), interleukin (IL)-6 (Rn00561420_m1), cyclooxygenase-2 (Cox-2) (Rn00568225_m1), RelA (Rn01502266_m1), CD31 (Rn01467259_m1), Albumin (Rn01413833_m1), CD68 (Rn01495643_g1) and tissue inhibitor of metalloproteinase (TIMP)-3 (Rn00441826_m1).

Nuclear factor-κB siRNA transfection

HSC-2 cells were seeded at a density of 106 per 100 mm cell culture dish and incubated at 37°C. The siRNA was mixed at a final concentration of 10 nmol/L with 1 mL DMEM without serum and 120 μL HiPerfect transfection reagent (Qiagen, Germany) and incubated for 10 min. The mixture was added drop-wise to the cells and incubated for 48 h. For the mock control, only the HiPerfect reagent was used. The ON-Targetplus nuclear factor (NF)-κB siRNAs used were J-080033-11 and J-080033-12 (Dharmacon, Lafayette, CO, USA). These conditions were tested for transfection efficiency using FITC-labeled siRNA and FACS analysis.

Overexpression of miR-146a in an HSC cell line

The vector was constructed by amplification of a 487-bp fragment containing the rno-miR-146a from rat genomic DNA using the following primer pair: sense 5'-AAGCTTGCCACCAGTCCCATCCTTCACC-3' (HindIII), anti-sense 5'-GGATCCTTCCTCTGTGCTGGGATTACAGGGTG-3' (BamHI). After sub-cloning, the rno-miR-146a was excised using BamHI/EcoRV and cloned into pcDNA6.2/GW EmGFP-miR (Invitrogen). The HSC-2 cells were stably transfected with the construct using Lipofectamine 2000 (Invitrogen) and selected in cell culture medium supplemented with 10 μg/mL Blasticidin. The clonal selection was achieved using FACS.

Gene expression array and analysis

Total RNA from HSC-2 cells overexpressing miR-146a and control cells (two different passages) were used to study the transcriptome changes using the GeneChip Rat Genome 230 2.0 (Affymetrix, USA). The preparation of the samples was performed according to the technical manual P/N 702232 Rev. 3 (Affymetrix) using one-cycle cDNA and target labeling. The chips were scanned using a Genechip Scanner 3000 (Affymetrix). The raw datasets were deposited under #GSE19463 at the GEO repository[12].

The microarray probe set data was summarized using the Robust Multi-Array Average expression measure method, and pre-processed to correct unreliable (small) intensities for each array. The pre-processed data were then normalized using the Cross-Correlation method[13]. For each gene, a fold change value was calculated for samples vs control. Differentially expressed genes (DEGs) were selected based on the criterion of fold change > 2. The P values of DEGs were obtained using one-tailed Student’s t test. Pathway analysis was carried out on the DEGs using Ingenuity Pathway Analysis (Ingenuity Systems).

Transfection of miRNA mimics and hairpin-inhibitor

Cells were seeded at 20 000 per well in 48-well plates 24 h prior to transfection. The miRNA mimics or hairpin-inhibitor were added at the required final concentration (miR-26a, 146a, controls and quadruple transfection: 50 nmol/L each; miR-29a and 214: 200 nmol/L each) to 750 μL DMEM without serum, followed by 10 μL HiPerfect transfection reagent. The mixture was incubated for 10 min. The medium from each well was aspirated and replaced by 250 μL of the mixture. The transfection was performed in triplicate. Controls were either HiPerfect reagent only (mock) or control miRNAs for the mimic and/or inhibitor.

SDS-PAGE and Western blotting

Cells were lysed in ProteoJet lysis buffer (#K0301; Fermentas, Glen Burnie, MD, USA) and the protein concentration was estimated using the BCA method (Thermo Scientific, USA). The samples were separated in 4%-12% Bis-Tris NuPage gels (Invitrogen) and transferred onto nitrocellulose membranes. The membranes were blocked for 1 h at room temperature using 5% non-fat milk in TBS-Tween (TBS-T). The primary antibodies were applied in the following dilutions: interleukin receptor associated kinase 1 (IRAK1) (sc-7883; Santa Cruz Biotechnology, Santa Cruz, CA, USA,) 1:400; tumor necrosis factor receptor associated factor 6 (TRAF6) (sc-7221; Santa Cruz Biotechnology) 1:400; IκBα (#4814; Cell Signaling, Danvers, MA, USA) 1:1000; pIκBα (#2859; Cell Signaling) 1:750; Cox-2 (sc-1747; Santa Cruz Biotechnology) 1:5000; and β-actin (ab-8227; Abcam, Cambridge, UK) 1:5000. After three washes in TBS-T, the appropriate HRP-conjugated secondary antibody was given at 1:2000 dilution in blocking solution. After three washes in TBS-T, the membrane was developed using the chemiluminiscence substrate (Millipore, Billerica, MA, USA). Primary and secondary antibodies were incubated at 4°C overnight and 1 h at room temperature, respectively.

Electrophoretic mobility shift assay

Nuclear protein extract from rno-miR-146a-overexpressing clones was obtained using the NE-PER Nuclear and Cytoplasmic Extraction kit (Thermo Scientific). The electrophoretic mobility shift assay (EMSA) was performed using the NF-κB(I) EMSA kit according to its protocol (AY1030; Panomics, USA), as described previously[17]. The samples were separated in a 6% non-denaturing polyacrylamide gel (Invitrogen) and transferred to a nylon membrane.

Immunohistochemistry and staining of liver sections

Slides were de-paraffinized and the antigen retrieved by heat exposure in the Target Retrieval Solution pH 9 (S2367; Dako, Glostrup, DK) using a 2100-Retriever retrieval steamer for 45 min. The endogenous peroxidase was blocked with 3% H2O2 in methanol for 15 min. Protein was blocked in 10% normal goat serum in PBS for 20 min. The slides were incubated with mouse anti-human SMAA (M0851; Dako) at 1:100 dilution for 1 h, washed and incubated with an anti-mouse HRP-conjugated antibody (K4001; Dako) for 30 min, and developed with DAB (K3468; Dako). All incubations were carried out at room temperature. Nuclei were counter stained with hematoxylin. Hematoxylin and eosin and Sirius Red staining was performed according to standard protocols on paraffin sections. Bright-field images were taken with the LEICA RMB-DM epifluorescence microscope (LEICA, Germany).

Statistics

All quantitative data were presented as mean ± SE. Experimental data were analyzed using the two-tailed Student’s t test assuming equal variances. P ≤ 0.05 was considered significant. The time-dependent changes during in vitro HSC activation were tested for significance at the 0.05 level using one-way ANOVA and Bonferroni’s post-hoc test. The array data were normalized and analyzed as described in the respective sections above.

RESULTS

Identification of differentially regulated miRNAs in in vitro activated pHSCs and comparison to in vivo activated pHSCs

In 10-d in vitro activated pHSCs, 16 miRNAs were upregulated and 26 were downregulated significantly in comparison to quiescent pHSCs (Table 1). We included miR-29a, although the P value was above the threshold of 0.05, for further studies because of its predicted targets, which consisted of a number of collagens. The microarray data were confirmed for a number of chosen miRNAs (let-7b, 7c, miR-16, 26a, 29a, 31, 125b, 143, 146a, 150 and 214) using real-time PCR in three additional experiments (Figure 3A). Using isolated in vivo activated pHSCs from rats on CDE diet, we found that only miRNAs let-7b, 7c, miR-31, 143 and 214 showed the same regulation as observed for the in vitro activated pHSCs (Figure 3B).

Figure 3.

Figure 3

Verification of microarray data by real-time polymerase chain reaction of 11 differentially regulated miRNAs and their regulation upon in vivo activation of hepatic stellate cells. A: The graph depicts the changes in the miRNA expression of 11 miRNAs detected by real-time polymerase chain reaction, comparing quiescent with 10-d culture activated primary hepatic stellate cells (pHSCs). The data represent the mean ± SE of three independent experiments (aP ≤ 0.05, bP ≤ 0.005); B: The graph illustrates the relative expression levels of miRNAs in isolated in vivo activated pHSCs (n = 4, choline-deficient ethionine supplemented diet) compared to normal diet (n = 2) (aP ≤ 0.05, bP ≤ 0.005).

Pathway analysis for differentially regulated miRNAs in in vitro activated pHSCs

We performed a pathway analysis using the predicted targets of the differentially regulated miRNAs. The enrichment of genes in single pathways is shown as the -log of the P value (P ≤ 0.001). Signaling pathways which were affected include endothelin-1, cyclin-dependent kinase 5, extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK), p70S6K, chemokine, bone morphogenetic protein (BMP) and IL-6 for the upregulated miRNAs, as well as ERK/MAPK, production of NO and reactive oxygen species (ROS), AMP activated protein kinase (AMPK), transforming growth factor (TGF)-β, integrin, cAMP-mediated signaling and phosphatase and tensin homolog (PTEN) for the downregulated miRNAs (Figure 4A and B).

Figure 4.

Figure 4

Predicted targets of all differentially regulated miRNAs during in vitro activation of primary hepatic stellate cells (Table 1) were analyzed. The two charts represent the enrichment of molecules in affected pathways for the upregulated (A) and downregulated (B) miRNAs. Only pathways with P ≤ 0.001 are shown. IGF-1: Insulin-like growth factor-1; ERK: Extracellular signal-regulated kinase; MAPK: Mitogen-activated protein kinase; BMP: Bone morphogenetic protein; IL: Interleukin; ROS: Reactive oxygen species; AMPK: AMP activated protein kinase; TGF: Transforming growth factor; PTEN: Phosphatase and tensin homolog; LXR: Liver X receptor; RXR: Retinoid X receptor; PPAR: Peroxisome proliferator-activated receptor; HGF: Hepatocyte growth factor.

Overexpression of miR-146a in HSC-2 and transcriptome analysis

Studies have shown that miR-146a is linked to inflammation and the NF-κB pathway through the two known targets IRAK1 and TRAF6[18,19]. In order to study the function of miR-146a in activated HSCs in vitro, we overexpressed this miRNA in a HSC cell line HSC-2[11]. The level of miR-146a in this cell line is very low, making it suitable for the overexpression. The expression of the reporter green fluorescent protein and the real-time PCR validation of the miR-146a expression (Figure 1B) provided evidence for the successful overexpression of miR-146a in three different clones (S1, S4 and S5).

IRAK1 and TRAF6 are direct targets of miR-146a with two target sites for each mRNA (Figure 5A). We were able to show downregulation of these proteins in all three clones (Figure 5B). The functional consequence of this downregulation can be seen by suppression of the phosphorylation of IκB at Ser32 (Figure 5B). The reduced phosphorylation of IκB in turn should lead to the retention of NF-κB in the cytoplasm. Indeed, our EMSA illustrated that there was reduced nuclear binding activity of NF-κB to an NF-κB probe in all clones (Figure 5C). One of the genes regulated by NF-κB is Cox-2, which is functionally related to HSCs due to its pro-apoptotic effect on HSCs[20,21]. Therefore, we investigated the protein level of Cox-2 in the miR-146a-overexpressing clones, and found the expected downregulation (Figure 5D). Surprisingly, further investigation revealed that the mRNAs of NF-κB and Cox-2 were upregulated (Figure 5E). In contrast, we observed a significant downregulation of IL-6 mRNA, another target of NF-κB, in the clones S1, S4 and S5 (Figure 5E). We also found a significant upregulation of SMAA and collagen I (ColI) mRNAs, a HSC activation and a fibrotic marker, respectively (Figure 5E).

Figure 5.

Figure 5

Changes during overexpression of rno-miR-146a in the hepatic stellate cell-2 cell line. A: Depicted are two putative binding sites of miR-146a to the 3’-UTR of rat tumor necrosis factor receptor associated factor 6 (TRAF6) and rat interleukin receptor associated kinase 1 (IRAK1), respectively; B: The Western blotting data show the suppression of TRAF6 and IRAK1, resulting in the decreased phosphorylation of IκB, although the expression of IκB remained unchanged. A representative Western blotting for two independent experiments is shown; C: Electrophoretic mobility shift assay (EMSA) results demonstrated a decrease in nuclear factor (NF)-κB DNA binding activity due to the overexpression of miR-146a. TATA binding protein (TBP) showed equal loading of samples. A representative EMSA experiment is shown out of three independent samples for each clone; D: miR-146a-overexpressing clones showed a reduced level of cyclooxygenase-2 (Cox-2) protein. The Western blotting shown is representative of two independent experiments; E: The relative fold change in mRNA expression between hepatic stellate cell (HSC)-2 and miR-146a-overexpressing HSC-2 cells for five different targets [NF-κB (RelA), Cox-2, smooth muscle α-actin, ColI, interleukin-6] is shown. The data represent the mean ± SE of two independent experiments (aP ≤ 0.005).

In order to establish a link between the regulation of miR-146a and NF-κB activity, as proposed by Taganov et al[18], we transfected NF-κB siRNAs into HSC-2 cells. The efficiency of the transfection was shown by the downregulation of NF-κB in total cell lysates and nuclear extracts, which resulted in a decrease in NF-κB DNA binding activity (Figure 6A and B, respectively). We also found downregulation of miR-146a in NF-κB siRNA-transfected cells, thereby confirming a regulation of miR-146a by NF-κB in HSCs (Figure 6C). Surprisingly, we noticed an increase in the Cox-2 protein expression (Figure 6D), which implied a yet unclear involvement of miR-146a in the regulation of this enzyme.

Figure 6.

Figure 6

Regulation of miR-146a by nuclear factor-κB. A: Knock-down experiments using nuclear factor (NF)-κB siRNAs showed a reduced level of cellular NF-κB (RelA) protein; B: The nuclear level of NF-κB (RelA) was decreased and showed a diminished DNA binding activity. Depicted is a representative Western blotting and electrophoretic mobility shift assay from three independent experiments; C: Downregulation of NF-κB (RelA) mRNA due to NF-κB siRNA transfection was accompanied by a decrease in miR-146a after 24 h. The data represent the mean ± SE of two independent experiments (aP ≤ 0.05, bP ≤ 0.01, cP ≤ 0.001); D: Cyclooxygenase-2 (Cox-2) protein was upregulated after NF-κB siRNA transfection. Shown are a representative Western blotting and the densitometric analysis of six independent experiments (aP ≤ 0.05).

The differences in the NF-κB-dependent regulation of Cox-2 and IL-6 have already hinted at the intricacy of the influence of the miR-146a overexpression has on the gene expression in activated HSCs. In order to get an overview of the transcriptome changes, we performed a gene expression analysis of the three miR-146a-overexpressing clones, and compared them with control cells using a cDNA microarray. The analysis yielded 485 up- and 309 downregulated transcripts (Supplementary Tables 1 and 2), which satisfied a P value ≤ 0.05 and at least twofold change. Among the upregulated genes were Lmcd1, CD81, FGF13, Col4a1, Cadherin 11 and BMP-4. The highly downregulated genes included Col15a1, MMP-2, Thy-1, IL-1RL1 and Cadherin 13.

Supplementary Table 1.

Upregulated genes in miR-146a-transfected hepatic stellate cell-2

Probe ID Representative public ID Gene symbol Gene title Log2 Fold change P-value
1383164_at AW524366 5.065854 33.49455 3.49E-05
1379902_at BE108170 4.568453 23.72692 0.000154
1382211_at AI602542 4.401705 21.1371 0.008197
1394456_at AW525722 3.905818 14.98885 0.000414
1373740_at AA851385 3.777603 13.71424 0.002694
1393437_at AW142608 3.417765 10.68685 3.36E-05
1389579_at BI284372 3.412511 10.64801 0.010102
1374065_at BG378920 3.327195 10.03658 0.000137
1393018_at AI071984 3.323743 10.01259 0.000201
1392105_at AW527533 3.22946 9.379166 0.005625
1373062_at BM388650 3.174909 9.031143 0.00033
1373776_at AI406341 3.127483 8.73909 3.23E-06
1378457_at AI179450 2.993031 7.96145 0.001547
1391428_at AI639162 2.959079 7.776274 0.003728
1393314_at BI289840 2.826721 7.0946 8.14E-05
1379382_at AI144865 2.810339 7.014492 0.01755
1391481_at BE104424 2.742723 6.693324 0.000235
1376435_at BI303340 2.688229 6.445217 0.00028
1395327_at AW522341 2.651476 6.283098 0.017329
1371506_at AA891207 2.611623 6.111911 0.013546
1394833_at BE120930 2.604706 6.082676 3.53E-06
1375230_at AA800192 2.512936 5.707806 0.000375
1374811_at AA858705 2.505232 5.677406 0.035302
1377934_at BF387289 2.461691 5.508619 0.005853
1383240_at BE110753 2.374072 5.184023 0.004602
1372921_at AI073219 2.355729 5.118529 0.036703
1376800_at AA892496 2.321059 4.99699 0.000124
1384137_at AI030318 2.265411 4.807915 0.000711
1398597_at AI044699 2.200111 4.595148 0.00022
1393782_at BF396790 2.19007 4.563275 0.003901
1382330_at BE116838 2.188725 4.559023 0.000179
1398657_at AI045896 2.164482 4.483053 5.91E-05
1376617_at BE107482 2.109346 4.314957 0.001578
1378111_at AI576002 2.104523 4.300555 0.023
1379936_at AA875132 2.096645 4.277136 0.005892
1377946_at BF420043 2.071766 4.20401 3.19E-05
1377675_at AI177743 2.063136 4.178936 0.005112
1380940_at BF402603 2.04682 4.131942 0.007683
1381335_at BE349658 2.046725 4.131669 7.30E-05
1374971_at AA818954 2.036171 4.101556 0.000603
1397781_at BF414751 1.968385 3.913299 0.004705
1391841_at BE103537 1.948096 3.858649 0.003749
1388546_at AI013328 1.918544 3.780415 0.005524
1379444_at BF283694 1.836166 3.570599 0.00094
1392627_x_at BI282114 1.828818 3.552459 9.63E-05
1374432_at BE118251 1.820423 3.531847 0.023594
1389239_at BM384377 1.820056 3.530949 3.85E-06
1394578_at BI299761 1.783117 3.441689 0.019487
1376734_at BI279030 1.776063 3.424903 0.021384
1392820_at BI285064 1.763119 3.394312 0.000366
1382212_at AI385201 1.761883 3.391405 0.008303
1374273_at BG665433 1.740316 3.341083 0.001848
1390471_at BM383411 1.732112 3.322138 0.003308
1396009_at BE108258 1.726446 3.309117 2.68E-05
1382294_at AI576111 1.698452 3.245526 0.004164
1390459_at BG670247 1.683832 3.212802 0.000503
1381577_at AI170131 1.674706 3.192544 9.98E-05
1388720_at BM390713 1.669188 3.180356 0.000841
1371394_x_at BG664827 1.660846 3.162018 0.000385
1379719_at AI408386 1.629839 3.094784 8.76E-06
1392876_at BG375098 1.597297 3.025758 0.000425
1377881_at AA997027 1.583295 2.996534 0.000249
1392924_at BG371591 1.573984 2.977258 2.15E-05
1378152_at AI170349 1.572157 2.97349 0.000818
1390987_at AI406858 1.539611 2.907161 0.005124
1390300_at BM383635 1.539317 2.906568 0.001988
1381996_at BG666712 1.524793 2.877454 0.007289
1392893_a_at AA926239 1.492644 2.814042 1.82E-05
1378462_at BE107396 1.484439 2.798083 0.027693
1391028_at AI511126 1.480597 2.790641 0.002716
1385978_at AI072788 1.48007 2.789622 0.01557
1392813_at AI548994 1.472777 2.775556 0.028907
1379903_at AI059853 1.456459 2.744339 0.005294
1382291_at AI454332 1.447251 2.726879 0.021889
1396539_at BE119221 1.444627 2.721924 0.00325
1395381_at BF542239 1.428428 2.691532 0.018331
1394709_at AI406967 1.426754 2.688412 0.013879
1378780_at BF410325 1.42094 2.677598 0.009832
1374172_at AI010883 1.407256 2.652321 0.005074
1377551_at BE118580 1.406921 2.651706 0.000613
1378172_at AI008119 1.390207 2.621164 9.29E-05
1389744_at AW527194 1.371756 2.587854 0.029149
1393728_at AA964541 1.361978 2.570373 0.00664
1389284_at BI275747 1.352525 2.553586 0.009308
1377309_at AA963085 1.344539 2.53949 0.000217
1394012_at BI303933 1.325072 2.505453 9.03E-06
1396886_at BF387869 1.319644 2.496045 0.000671
1389172_at AI179391 1.318725 2.494456 5.03E-06
1376011_at AI411359 1.31543 2.488765 0.013276
1374171_at AI170507 1.313956 2.486224 0.003317
1382802_x_at AW920828 1.313169 2.484867 0.0032
1395211_s_at BE118557 1.294366 2.452692 0.014857
1391727_at BG662710 1.294339 2.452646 0.001351
1373079_at BI296427 1.291969 2.448621 0.040034
1375005_at BF403824 1.291727 2.44821 0.001959
1382174_at AI227996 1.290673 2.446421 0.006458
1380088_at AW533021 1.284168 2.435415 5.37E-05
1383910_at BF398220 1.28089 2.429889 0.003117
1381498_at AA956116 1.226183 2.339473 0.001176
1391936_a_at BI289110 1.212511 2.317406 0.041362
1379089_at BM382838 1.20837 2.310764 0.000681
1372993_at BI299621 1.204492 2.304561 0.000924
1390671_at AI044666 1.203424 2.302856 0.001722
1394916_at AW526714 1.202724 2.301739 0.001978
1389397_at AI234012 1.202426 2.301263 0.000195
1376637_at AI102401 1.198002 2.294217 0.027098
1386552_at BF284027 1.197145 2.292856 0.003348
1377792_at AW524891 1.195075 2.289568 0.013872
1384952_at AI028968 1.184453 2.272772 0.001744
1376768_at BM386807 1.182682 2.269984 0.008644
1389127_at BF552908 1.17877 2.263837 0.001451
1392140_at BF419584 1.174126 2.256561 0.010974
1375707_at AA817993 1.171668 2.25272 0.017511
1377994_at AI501237 1.165986 2.243866 2.56E-05
1372027_at AI009713 1.165036 2.242388 0.004861
1374290_at AI408191 1.161834 2.237416 0.000514
1372820_at BE109102 1.157167 2.23019 6.76E-05
1395629_at BE105336 1.152754 2.223379 0.001122
1373628_at AA818342 1.148702 2.217143 0.003268
1383697_at AW530905 1.14753 2.215342 0.000199
1384269_at BF386887 1.144996 2.211455 0.039498
1379733_at BF396474 1.144326 2.210428 0.000479
1379682_at BI281668 1.138058 2.200846 0.00129
1393334_at AW528448 1.134957 2.19612 0.000111
1372583_at AI009094 1.134834 2.195932 0.000776
1390193_at BF389884 1.132371 2.192188 0.007448
1373114_at AI408442 1.132006 2.191632 0.026188
1395586_at BF545930 1.130756 2.189735 0.009671
1389085_at BI296359 1.122011 2.176502 0.033565
1378898_at BE109293 1.117104 2.169111 0.018502
1384433_at AI072153 1.116005 2.167459 0.008374
1392778_at AA891634 1.112387 2.16203 0.000734
1372515_at BI281177 1.109794 2.158148 0.000373
1394727_at AI407942 1.104267 2.149896 0.000884
1391617_at AI171103 1.103278 2.148422 0.00173
1384680_at AA924336 1.103174 2.148268 1.20E-05
1374246_at BF402392 1.100807 2.144746 0.001207
1395350_at AW919190 1.100062 2.14364 0.02672
1397343_at BE113258 1.098815 2.141787 0.000702
1384051_at BF390066 1.096884 2.138923 0.00037
1381654_at BF398637 1.086982 2.124292 0.008757
1392619_at BE118107 1.081379 2.116058 0.010153
1376747_at BE107075 1.079554 2.113382 0.014697
1380763_at AI101194 1.078476 2.111804 0.008553
1393653_at BM384831 1.077241 2.109997 0.029779
1379844_at AW531072 1.073984 2.105239 0.00402
1394948_at BI303527 1.073384 2.104364 0.028955
1393911_at AI502300 1.069942 2.099349 0.001054
1378006_at AI233832 1.069145 2.09819 0.00023
1379451_at AI549081 1.069122 2.098155 0.025226
1391643_at BI290758 1.065858 2.093415 0.009922
1390136_at BE109274 1.062274 2.08822 0.003245
1389256_at BG381256 1.061409 2.086969 0.02736
1376465_at BI295240 1.055842 2.078931 0.025628
1390515_at AA998383 1.05246 2.074063 0.003395
1390205_at BE108876 1.052183 2.073665 0.000145
1374728_at BG671786 1.050605 2.071399 0.043671
1394883_at AI179616 1.050405 2.071111 0.038398
1372104_at BF289002 1.043745 2.061573 0.000585
1379252_at AW522833 1.041529 2.058408 0.000451
1377151_at AI102833 1.040228 2.056553 0.00364
1377880_at AI170633 1.038506 2.054099 0.00023
1389908_at BE107167 1.035223 2.049431 0.01567
1373082_at AA893743 1.033904 2.047558 0.017691
1373537_at BE113175 1.028307 2.039629 0.005797
1392578_at AI070875 1.021081 2.029439 0.01047
1377705_at BF549971 1.019922 2.027809 0.001107
1371854_at BG374451 1.019759 2.02758 0.012677
1375647_at BG671943 1.006159 2.008556 0.017266
1385903_at AA859627 1.004338 2.006023 0.000426
1398265_at NM_013040 Abcc9 ATP-binding cassette, sub-family C (CFTR/MRP), member 9 1.43783 2.70913 0.001785
1387287_a_at D83598 Abcc9 ATP-binding cassette, sub-family C (CFTR/MRP), member 9 1.223092 2.334465 0.004574
1397375_at BM384537 Acsl5 Acyl-CoA synthetase long-chain family member 5 1.153318 2.224249 0.01568
1386926_at NM_053607 Acsl5 Acyl-CoA synthetase long-chain family member 5 1.053592 2.075692 0.015907
1370857_at BI282702 Acta2 Smooth muscle α-actin 2.229514 4.68976 0.000129
1398294_at NM_031005 Actn1 Actinin, α 1 1.131925 2.191509 0.001329
1368223_at NM_024400 Adamts1 ADAM metallopeptidase with thrombospondin type 1 motif, 1 2.048565 4.136942 0.028144
1376481_at BF416285 Adamts9 A disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 9 2.392634 5.251154 0.000223
1374535_at BI283881 Afap1l2 Actin filament associated protein 1-like 2 2.203032 4.60446 0.000634
1368869_at BG663107 Akap12 A kinase (PRKA) anchor protein 12 1.529713 2.887284 0.019479
1368868_at NM_057103 Akap12 A kinase (PRKA) anchor protein 12 1.010475 2.014575 0.013205
1387493_at NM_133515 Akap5 A kinase (PRKA) anchor protein 5 1.569515 2.968049 0.003304
1370043_at NM_031753 Alcam Activated leukocyte cell adhesion molecule 1.603863 3.039561 0.010096
1383469_at BG377269 Aldh1a3 Aldehyde dehydrogenase 1 family, member A3 1.116847 2.168725 0.00291
1370638_at AF069525 Ank3 Ankyrin 3, epithelial 1.818441 3.526998 0.00833
1367664_at NM_013220 Ankrd1 Ankyrin repeat domain 1 (cardiac muscle) 1.668973 3.179881 0.020907
1367665_at L81174 Ankrd1 Ankyrin repeat domain 1 (cardiac muscle) 1.503501 2.8353 0.035713
1372069_at BF284716 Ankrd15 Ankyrin repeat domain 15 1.333618 2.520339 0.003331
1367974_at NM_012823 Anxa3 Annexin A3 3.372176 10.35443 7.22E-05
1367975_at BF283732 Anxa3 Annexin A3 1.914777 3.770554 0.000113
1395313_s_at AI179982 Anxa3 Annexin A3 1.717191 3.287957 0.000365
1373654_at BM389254 Anxa8 Annexin A8 1.14259 2.20777 0.000179
1392815_at BE114489 Arap2 ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2 1.501088 2.830562 0.000231
1387018_at NM_053770 Argbp2 Arg/Abl-interacting protein ArgBP2 1.513378 2.854778 0.039786
1373315_at AI176425 Arnt2 Aryl hydrocarbon receptor nuclear translocator 2 2.041125 4.115662 0.023949
1378134_at BI291629 Atp8b1 ATPase, Class I, type 8B, member 1 1.061725 2.087426 7.68E-05
1368485_at NM_024401 Avil Advillin 2.121568 4.351667 0.012237
1370823_at AF387513 Bambi BMP and activin membrane-bound inhibitor, homolog (Xenopus laevis) 1.526089 2.880041 0.003285
1372613_at AI232784 Bdh2 3-hydroxybutyrate dehydrogenase, type 2 1.177434 2.261742 0.013257
1387232_at NM_012827 Bmp4 Bone morphogenetic protein 4 3.074538 8.424189 0.000456
1380459_at AI555023 Btbd14a BTB (POZ) domain containing 14A 1.35767 2.562709 3.53E-06
1386995_at BI288701 Btg2 B-cell translocation gene 2, anti-proliferative 1.228055 2.342509 0.004008
1377086_at AI233530 C1qtnf3 C1q and tumor necrosis factor related protein 3 2.513168 5.708723 0.002654
1376657_at BE117767 Cadm1 Cell adhesion molecule 1 1.04091 2.057525 0.001137
1393452_at BM391835 Car9 Carbonic anhydrase 9 2.22363 4.670671 0.00011
1390101_at AI170609 Ccdc107 Coiled-coil domain containing 107 1.152965 2.223704 0.000166
1398827_at NM_013087 Cd81 Cd81 molecule 3.901095 14.93986 0.00033
1388936_at BI296340 Cdh11 Cadherin 11 3.493679 11.26425 0.016743
1370371_a_at U23056 Ceacam1 /// Ceacam10 Carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) /// carcinoembryonic antigen-related cell adhesion molecule 10 2.350728 5.100814 0.001261
1393142_at BF562621 Cep70 Centrosomal protein 70 kDa 1.414308 2.665318 5.96E-05
1368675_at NM_032084 Chn2 Chimerin (chimaerin) 2 1.111248 2.160324 0.00013
1389368_at AW253242 Cnksr3 Cnksr family member 3 1.115693 2.166991 0.002136
1376868_at BM389293 Cobll1 Cobl-like 1 2.807857 7.002435 0.002758
1372439_at AI176393 Col4a1 Collagen, type IV, α 1 3.587058 12.01745 4.28E-05
1373245_at BE111752 Col4a1 Collagen, type IV, α 1 3.148631 8.868134 9.98E-05
1388494_at BI281705 Col4a2 Collagen, type IV, α 2 2.800595 6.967276 0.000478
1393891_at BE128699 Col8a1 Collagen, type VIII, α 1 1.15147 2.221401 0.003468
1367782_at NM_012812 Cox6a2 Cytochrome c oxidase, subunit VIa, polypeptide 2 2.245734 4.742785 0.001312
1386921_at NM_013128 Cpe Carboxypeptidase E 2.564823 5.916823 0.021482
1382037_at AI600057 Crim1 Cysteine rich transmembrane BMP regulator 1 (chordin like) 2.041047 4.11544 0.00285
1391448_at BI289620 Crim1 Cysteine rich transmembrane BMP regulator 1 (chordin like) 1.9156 3.772706 0.000387
1398622_at AI703807 Crim1 Cysteine rich transmembrane BMP regulator 1 (chordin like) 1.80839 3.502512 0.000527
1376457_at AI175861 Crispld2 Cysteine-rich secretory protein LCCL domain containing 2 1.37777 2.598664 0.018183
1387922_at AF109674 Crispld2 Cysteine-rich secretory protein LCCL domain containing 2 1.195518 2.29027 0.003604
1368059_at NM_053955 Crym Crystallin, mu 1.288402 2.442574 0.000395
1383590_at AA963863 Csgalnact1 Chondroitin sulfate N-acetylgalactosaminyltransferase 1 3.304007 9.876547 0.022018
1370057_at NM_017148 Csrp1 Cysteine and glycine-rich protein 1 1.030407 2.042601 0.001628
1388583_at BF283398 Cxcl12 Chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1) 2.092111 4.263716 0.042845
1387655_at AF189724 Cxcl12 Chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1) 1.643136 3.123441 0.028532
1369633_at AI171777 Cxcl12 Chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1) 1.567476 2.963858 0.045339
1368290_at NM_031327 Cyr61 Cysteine-rich, angiogenic inducer, 61 1.261651 2.397699 0.022554
1371436_at AI176924 Ddah2 Dimethylarginine dimethylaminohydrolase 2 1.710173 3.272001 0.006371
1368013_at NM_080399 Ddit4l DNA-damage-inducible transcript 4-like 1.056235 2.079498 0.002531
1389894_at BF399476 Dlc1 Deleted in liver cancer 1 1.068336 2.097013 0.002194
1377835_at BM390876 Dock8 Dedicator of cytokinesis 8 2.230319 4.692377 0.005526
1388506_at AW144509 Dsp Desmoplakin 1.830721 3.557148 9.48E-05
1368146_at U02553 Dusp1 Dual specificity phosphatase 1 1.560299 2.949149 0.003438
1368949_at NM_053820 Ebf1 Early B-cell factor 1 1.316466 2.490553 0.000315
1369519_at NM_012548 Edn1 Endothelin 1 1.366023 2.577591 0.009786
1368541_at NM_053719 Emb Embigin 1.064032 2.090767 0.031817
1377752_at BE112998 Emp2 Epithelial membrane protein 2 1.392599 2.625512 0.000189
1373617_at AA818807 Emp2 Epithelial membrane protein 2 1.347238 2.544246 0.000131
1377311_at AI045616 Emx2 Empty spiracles homeobox 2 1.032095 2.044992 0.001019
1369096_at NM_134331 Epha7 Eph receptor A7 1.427798 2.690358 0.001357
1385788_at AW534949 Ephb3 Eph receptor B3 1.321665 2.499544 0.000783
1369182_at NM_013057 F3 Coagulation factor III (thromboplastin, tissue factor) 2.945169 7.701657 8.99E-05
1377940_at BF398271 Fam101b Family with sequence similarity 101, member B 1.069187 2.09825 0.047471
1384507_at AA817708 Fam105a Family with sequence similarity 105, member A 1.169405 2.24919 0.00595
1389146_at BF283267 Fam107b Family with sequence similarity 107, member B 1.01668 2.023257 0.000409
1393910_at BF563961 Fam13a1 Family with sequence similarity 13, member A1 4.490284 22.47553 0.003831
1379625_at BG664461 Fam164a Family with sequence similarity 164, member A 1.550421 2.929026 0.001732
1384648_at AA963844 Fam164a Family with sequence similarity 164, member A 1.219281 2.328307 0.000456
1391944_at BI296237 Fam184a /// RGD1560557 Family with sequence similarity 184, member A /// similar to minichromosome maintenance protein 8 isoform 1 1.26856 2.409209 0.001168
1373286_at AA875261 Fblim1 Filamin binding LIM protein 1 1.055977 2.079126 0.000141
1376500_at AI639044 Fbxo23 F-box only protein 23 1.064218 2.091036 0.001619
1386614_at BG671466 Fbxo23 F-box only protein 23 1.016912 2.023583 0.010871
1368114_at NM_053428 Fgf13 Fibroblast growth factor 13 3.654623 12.59364 0.004204
1370106_at NM_019199 Fgf18 Fibroblast growth factor 18 2.48942 5.615522 0.016971
1369313_at NM_031677 Fhl2 Four and a half LIM domains 2 1.491713 2.812227 0.011052
1371951_at AA800031 Fhl2 Four and a half LIM domains 2 1.319164 2.495215 0.010936
1372825_at BI290551 Fnbp1 Formin binding protein 1 1.481808 2.792985 0.003539
1376784_at BI274481 Fnbp1 Formin binding protein 1 1.407572 2.652903 0.007946
1369471_at NM_138914 Fnbp1 Formin binding protein 1 1.142482 2.207604 0.012674
1377342_s_at BE105446 Fnbp1 Formin binding protein 1 1.043905 2.061801 0.023433
1370829_at M69056 Fntb Farnesyltransferase, CAAX box, β 2.00125 4.003468 0.001272
1368711_at NM_012743 Foxa2 Forkhead box A2 3.125513 8.727165 0.00498
1380387_at BE105492 Foxp2 Forkhead box P2 1.808179 3.501999 0.000372
1383721_at AI556075 Fzd8 Frizzled homolog 8 (Drosophila) 1.891668 3.710641 8.54E-05
1372016_at BI287978 Gadd45b Growth arrest and DNA-damage-inducible, β 1.287102 2.440374 0.007019
1369735_at NM_057100 Gas6 Growth arrest specific 6 2.030906 4.086614 0.000694
1367627_at NM_031031 Gatm Glycine amidinotransferase (L-arginine:glycine amidinotransferase) 1.704989 3.260264 0.001931
1390557_at BF394809 Gca Grancalcin 1.294802 2.453433 0.01519
1379031_at BM390697 Gca Grancalcin 1.132824 2.192876 0.01681
1374903_at AI234819 Gcnt2 Glucosaminyl (N-acetyl) transferase 2, I-branching enzyme 1.780391 3.435192 0.00076
1370375_at J05499 Gls2 Glutaminase 2 (liver, mitochondrial) 1.381886 2.606088 0.000222
1392888_at AI071251 Gpc4 Glypican 4 1.149833 2.218883 0.017197
1373773_at BF394166 Gpm6a Glycoprotein m6a 1.49299 2.814717 0.004487
1370389_at AB036421 Gpm6b Glycoprotein m6b 1.729687 3.316558 0.041126
1382955_at BI284296 Gpr126 G protein-coupled receptor 126 1.691914 3.230851 0.002139
1373693_at BF414143 Gprc5c G protein-coupled receptor, family C, group 5, member C 1.172596 2.254169 0.000245
1368618_at NM_031623 Grb14 Growth factor receptor bound protein 14 2.263062 4.800093 0.001165
1368401_at M85035 Gria2 Glutamate receptor, ionotropic, AMPA 2 1.185577 2.274543 0.038866
1383897_at BE117477 H2afy2 H2A histone family, member Y2 1.467448 2.765322 0.003118
1384541_at BM391441 Hapln1 Hyaluronan and proteoglycan link protein 1 2.720224 6.589753 0.021358
1370125_at NM_019189 Hapln1 Hyaluronan and proteoglycan link protein 1 2.532368 5.785206 0.010848
1368983_at NM_012945 Hbegf Heparin-binding EGF-like growth factor 1.057962 2.081988 0.018982
1376867_at BE095833 Hspc159 Galectin-related protein 2.821242 7.067707 0.000688
1373515_at BI275737 Hspc159 Galectin-related protein 2.64004 6.233487 0.000522
1387028_a_at M86708 Id1 Inhibitor of DNA binding 1 1.097822 2.140313 0.005605
1390507_at BI296097 Isg20 Interferon stimulated exonuclease 20 2.272905 4.832953 0.040035
1394824_at BF398348 Itga11 Integrin, α 11 1.885728 3.695395 0.000279
1393558_at AI137931 Itga6 Integrin, α 6 1.341112 2.533464 0.001146
1382439_at AI070686 Itgb6 Integrin, β 6 1.31697 2.491424 0.005869
1387907_at J05510 Itpr1 Inositol 1,4,5-triphosphate receptor, type 1 1.709204 3.269803 0.001386
1368725_at NM_019147 Jag1 Jagged 1 1.045878 2.064622 0.010981
1398124_at AI071356 Jazf1 JAZF zinc finger 1 1.325135 2.505564 1.36E-05
1396701_at BE110052 Kalrn Kalirin, RhoGEF kinase 1.050512 2.071265 0.00053
1369144_a_at NM_031739 Kcnd3 Potassium voltage gated channel, Shal-related family, member 3 1.978834 3.941744 0.01975
1394039_at BM382886 Klf5 Kruppel-like factor 5 1.168271 2.247422 0.001471
1368363_at NM_053394 Klf5 Kruppel-like factor 5 1.10729 2.154406 0.000169
1388932_at BI274917 Lama5 Laminin, α 5 1.49922 2.826898 0.008496
1367880_at NM_012974 Lamb2 Laminin, β 2 1.055487 2.07842 0.000777
1370993_at AA997129 Lamc1 Laminin, γ 1 1.144416 2.210566 0.001299
1388422_at BI275904 Lims2 LIM and senescent cell antigen like domains 2 3.226389 9.359224 0.000228
1376632_at AI602501 Lmcd1 LIM and cysteine-rich domains 1 3.919424 15.13088 0.000893
1381798_at BE114958 Lmo7 LIM domain 7 1.648918 3.135983 0.000383
1375726_at BI284480 Lmo7 LIM domain 7 1.223048 2.334393 0.000945
1381190_at AI598833 Lmo7 LIM domain 7 1.051248 2.072321 0.001218
1375523_at BE108178 LOC294446 Similar to Myristoylated alanine-rich C-kinase substrate (MARCKS) (ACAMP-81) 1.286331 2.43907 0.000713
1370948_a_at M59859 LOC294446 /// LOC681252 /// Marcks Similar to Myristoylated alanine-rich C-kinase substrate (MARCKS) (ACAMP-81) /// similar to Myristoylated alanine-rich C-kinase substrate (MARCKS) (Protein kinase C substrate 80 kDa protein) /// myristoylated alanine rich protein kinase C substrate 1.113014 2.162971 3.48E-05
1370949_at M59859 LOC294446 /// LOC681252 /// Marcks Similar to Myristoylated alanine-rich C-kinase substrate (MARCKS) (ACAMP-81) /// similar to Myristoylated alanine-rich C-kinase substrate (MARCKS) (Protein kinase C substrate 80 kDa protein) /// myristoylated alanine rich protein kinase C substrate 1.078213 2.111419 5.02E-05
1381434_s_at AW253721 LOC302022 Similar to nidogen 2 protein 1.462223 2.755326 0.002301
1373232_at AI008975 LOC302022 Similar to nidogen 2 protein 1.153904 2.225152 0.007223
1390158_at BI290752 LOC304903 Similar to Pappalysin-2 precursor (Pregnancy-associated plasma protein-A2) (PAPP-A2) (Pregnancy-associated plasma protein-E1) (PAPP-E) 1.089462 2.127947 0.01314
1384907_at AI411835 LOC306096 Similar to Dachshund homolog 1 (Dach1) 2.365997 5.155086 0.015526
1383888_at AA998264 LOC307495 Similar to biliverdin reductase B (flavin reductase (NADPH)) 1.345301 2.540832 6.23E-05
1379465_at AW527596 LOC311134 Hypothetical LOC311134 1.69193 3.230885 0.004884
1392074_at AA926082 LOC500046 Similar to hypothetical protein FLJ21986 1.886585 3.697589 0.042067
1392592_at AI137045 LOC679869 Similar to transcription factor 7-like 2, T-cell specific, HMG-box 1.098548 2.141391 0.000254
1394497_at AI535239 LOC679869 /// LOC683733 Similar to transcription factor 7-like 2, T-cell specific, HMG-box /// similar to Transcription factor 7-like 2 (HMG box transcription factor 4) (T-cell-specific transcription factor 4) (TCF-4) (hTCF-4) 1.055505 2.078445 0.000768
1373088_at BI295811 LOC682888 Hypothetical protein LOC682888 1.243831 2.368265 1.11E-06
1388447_at AA800701 LOC683626 Similar to limb-bud and heart 1.193694 2.287377 0.00702
1379815_at AI713959 LOC683733 Similar to Transcription factor 7-like 2 (HMG box transcription factor 4) (T-cell-specific transcription factor 4) (TCF-4) (hTCF-4) 1.406898 2.651664 1.15E-05
1377156_at BI273936 LOC683733 Similar to Transcription factor 7-like 2 (HMG box transcription factor 4) (T-cell-specific transcription factor 4) (TCF-4) (hTCF-4) 1.33204 2.517583 0.001391
1383488_at AA817785 LOC687536 Similar to Forkhead box protein F1 (Forkhead-related protein FKHL5) (Forkhead-related transcription factor 1) (FREAC-1) (Hepatocyte nuclear factor 3 forkhead homolog 8) (HFH-8) 1.534125 2.896127 0.003143
1386120_at BF393607 LOC689147 Hypothetical protein LOC689147 1.753785 3.372422 0.003982
1393414_at AW142650 LOC689176 Similar to transmembrane protein 64 1.20166 2.300042 0.047653
1376691_at AI103213 LOC689176 Similar to transmembrane protein 64 1.150453 2.219836 0.044249
1374016_at AI502597 Lpar1 Lysophosphatidic acid receptor 1 1.29975 2.461863 0.003803
1370048_at NM_053936 Lpar1 Lysophosphatidic acid receptor 1 1.268034 2.408331 0.001243
1389913_at BI276990 Lrrfip1 Leucine rich repeat (in FLII) interacting protein 1 1.260408 2.395635 0.000794
1368448_at NM_021586 Ltbp2 Latent transforming growth factor β binding protein 2 2.071905 4.204415 0.00222
1367768_at NM_031655 Lxn Latexin 1.381643 2.605649 0.000525
1374933_at BI277043 Mcam Melanoma cell adhesion molecule 1.00805 2.011191 0.034411
1369218_at NM_031517 Met Met proto-oncogene 1.253867 2.384798 0.000472
1384617_at AI385260 MGC72614 Hypothetical LOC310540 1.318517 2.494096 0.001888
1398387_at AI009530 MGC72614 Hypothetical LOC310540 1.263746 2.401184 0.001149
1367568_a_at NM_012862 Mgp Matrix Gla protein 3.353436 10.2208 0.010514
1384150_at AA901038 Mid1 Midline 1 1.062584 2.088669 0.000603
1370072_at NM_012608 Mme Membrane metallo endopeptidase 3.646308 12.52126 0.003799
1372457_at BF284182 Mtus1 Mitochondrial tumor suppressor 1 1.62914 3.093285 5.84E-06
1380321_at BI287786 Mtus1 Mitochondrial tumor suppressor 1 1.402213 2.643066 0.000159
1378970_at AW252385 Mybphl Myosin binding protein H-like 1.080283 2.114451 0.043933
1370158_at AA946388 Myh10 Myosin, heavy chain 10, non-muscle 1.192392 2.285314 0.005978
1388298_at BI279044 Myl9 Myosin, light chain 9, regulatory 1.368369 2.581786 0.025217
1389507_at AI072446 Nedd4l Neural precursor cell expressed, developmentally down-regulated 4-like 1.010244 2.014252 0.002318
1369679_a_at AB060652 Nfia Nuclear factor I/A 1.018188 2.025374 0.008943
1388618_at BM389302 Nid2 Nidogen 2 1.740644 3.341843 0.002285
1368883_at NM_030868 Nov Nephroblastoma overexpressed gene 1.914944 3.770993 0.010007
1371412_a_at BE107450 Nrep Neuronal regeneration related protein 1.740346 3.341152 0.003311
1369783_a_at U02319 Nrg1 Neuregulin 1 1.341273 2.533748 0.00085
1370607_a_at U02323 Nrg1 Neuregulin 1 1.322 2.500124 0.000298
1371211_a_at U02315 Nrg1 Neuregulin 1 1.304653 2.470242 0.000467
1382814_at AW521702 Odz3 Odz, odd Oz/ten-m homolog 3 (Drosophila) 2.65492 6.298115 0.004174
1377702_at BG380173 P2ry5 Purinergic receptor P2Y, G-protein coupled, 5 1.073159 2.104036 0.000211
1367687_a_at M25719 Pam Peptidylglycine α-amidating monooxygenase 1.192716 2.285826 0.021615
1398487_at BF419639 Pbx1 Pre-B-cell leukemia homeobox 1 1.092533 2.132481 0.006868
1393966_at AW530825 Pbx1 Pre-B-cell leukemia homeobox 1 1.018972 2.026474 0.000957
1370490_at L43592 Pcdhb12 Protocadherin β 12 1.40358 2.645572 0.026763
1377042_at BI288196 Pcgf5 Polycomb group ring finger 5 1.189904 2.281376 0.002754
1392773_at AA859578 Pcsk5 Proprotein convertase subtilisin/kexin type 5 1.589348 3.009134 0.002877
1393467_at BF549923 Pcsk5 Proprotein convertase subtilisin/kexin type 5 1.332597 2.518556 0.000461
1387812_at NM_012999 Pcsk6 Proprotein convertase subtilisin/kexin type 6 3.748654 13.44179 0.001431
1382345_at AA955299 Pctk2 PCTAIRE protein kinase 2 1.020874 2.029147 5.29E-05
1374157_at AA858930 Pde4b Phosphodiesterase 4B, cAMP specific 2.492088 5.625918 0.004862
1369044_a_at AF202733 Pde4b Phosphodiesterase 4B, cAMP specific 1.307088 2.474415 0.025797
1374616_at BM384311 Pdgfrl Platelet-derived growth factor receptor-like 1.872122 3.660707 1.96E-06
1368703_at NM_053326 Pdlim5 PDZ and LIM domain 5 1.360465 2.56768 0.000723
1386913_at NM_019358 Pdpn Podoplanin 2.706385 6.526842 0.01551
1374969_at AA799832 Pgm5 Phosphoglucomutase 5 1.9123 3.764087 4.83E-05
1368860_at NM_017180 Phlda1 Pleckstrin homology-like domain, family A, member 1 1.236279 2.355901 0.031298
1378106_at AI029402 Phlda2 Pleckstrin homology-like domain, family A, member 2 1.063574 2.090104 0.007195
1388539_at BE113268 Pkp2 Plakophilin 2 1.216333 2.323553 0.004529
1382659_at BF289229 Pla2r1 Phospholipase A2 receptor 1 1.81995 3.53069 5.56E-05
1387122_at NM_012760 Plagl1 Pleiomorphic adenoma gene-like 1 6.377022 83.11414 0.001611
1386962_at NM_024353 Plcb4 Phospholipase C, β 4 1.72799 3.31266 0.008873
1370489_a_at U57836 Plcb4 Phospholipase C, β 4 1.479277 2.78809 0.007828
1369029_at NM_057194 Plscr1 Phospholipid scramblase 1 1.321345 2.49899 0.002555
1370247_a_at AA943163 Pmp22 Peripheral myelin protein 22 1.312653 2.483979 0.000418
1372531_at BE106488 Ppfibp2 PTPRF interacting protein, binding protein 2 (liprin β 2) 1.798887 3.479517 0.023491
1393082_at AI044747 Ppp1r14c Protein phosphatase 1, regulatory (inhibitor) subunit 14c 1.263639 2.401006 0.009828
1368716_at NM_133425 Ppp1r14c Protein phosphatase 1, regulatory (inhibitor) subunit 14c 1.085918 2.122725 0.010686
1370012_at NM_031557 Ptgis Prostaglandin I2 (prostacyclin) synthase 1.878328 3.676486 0.007631
1368527_at U03389 Ptgs2 Prostaglandin-endoperoxide synthase 2 1.723796 3.303044 0.03712
1377427_at BE104739 Ptpn14 Protein tyrosine phosphatase, non-receptor type 14 1.140142 2.204028 1.10E-05
1374774_at BF552241 Ptpn14 Protein tyrosine phosphatase, non-receptor type 14 1.065112 2.092332 3.73E-05
1368035_a_at X83505 Ptprf Protein tyrosine phosphatase, receptor type, F 2.196463 4.583543 0.005199
1384227_at AI044031 Ptprk Protein tyrosine phosphatase, receptor type, K, extracellular region 2.172519 4.508097 4.14E-05
1390034_at BF393945 Ralgps2 Ral GEF with PH domain and SH3 binding motif 2 1.192882 2.286089 0.025134
1367791_at NM_031645 Ramp1 Receptor (G protein-coupled) activity modifying protein 1 1.90732 3.751116 0.017043
1368660_at NM_021690 Rapgef3 Rap guanine nucleotide exchange factor (GEF) 3 1.018953 2.026448 0.003623
1390159_at AA819332 Rasgrp3 RAS guanyl releasing protein 3 (calcium and DAG-regulated) 1.433832 2.701633 0.016442
1383322_at BG375198 Rasl11b RAS-like family 11 member B 1.75778 3.381775 0.008884
1387581_at NM_022959 Rassf9 Ras association (RalGDS/AF-6) domain family (N-terminal) member 9 2.580119 5.97989 2.33E-07
1383247_a_at BI291029 rCG_35099 Spinster homolog 2 1.270831 2.413004 0.006005
1388791_at BI275911 RGD1309930 Similar to 2810022L02Rik protein 1.327569 2.509794 0.01678
1395336_at BE098691 RGD1309930 Similar to 2810022L02Rik protein 1.309761 2.479005 0.004198
1374898_at AW527473 RGD1311422 Similar to CG8841-PA 1.039847 2.056009 0.002294
1373584_at BE113205 RGD1559643 Similar to hypothetical protein A430031N04 1.01952 2.027245 0.00071
1372380_at AI231308 RGD1561067 Similar to RNA binding protein gene with multiple splicing 3.350875 10.20267 0.002486
1375898_at AW252379 RGD1561067 Similar to RNA binding protein gene with multiple splicing 3.091972 8.526606 0.004328
1376619_at AI412803 RGD1561090 Similar to protein tyrosine phosphatase, receptor type, D 2.03385 4.094962 1.02E-06
1374591_at AI409042 RGD1561090 Similar to protein tyrosine phosphatase, receptor type, D 1.973152 3.926251 2.32E-05
1376919_at BG665267 RGD1562317 Similar to expressed sequence AW212394 1.376378 2.596157 0.000204
1388879_at BG669292 RGD1562717 Similar to ABI gene family, member 3 (NESH) binding protein 1.796298 3.473277 0.026049
1388906_at BM389311 RGD1564174 Similar to novel protein similar to Tensin Tns 1.157511 2.230722 4.32E-05
1383398_at AI059150 RGD1564327 Similar to integrin α 8 1.649388 3.137005 0.000121
1385354_at BE120766 RGD1564327 Similar to integrin α 8 1.472111 2.774276 9.05E-07
1376546_at BE120498 RGD1565432 Similar to hypothetical protein 1.921295 3.787629 0.009661
1396347_at BF395640 RGD1565926 RGD1565926 1.020952 2.029258 0.010695
1371731_at AI408151 RGD1566215 Similar to Coatomer γ-2 subunit (γ-2 coat protein) (γ-2 COP) 1.928401 3.806332 5.12E-05
1380425_at AI012859 Rnasel Ribonuclease L (2',5'-oligoisoadenylate synthetase-dependent) 1.671401 3.185237 0.002887
1377116_at BI301478 Rnasel Ribonuclease L (2',5'-oligoisoadenylate synthetase-dependent) 1.626917 3.088523 0.001458
1381533_at AI144754 Rnd1 Rho family GTPase 1 1.196579 2.291955 0.000495
1379693_at AI409154 Robo2 Roundabout, axon guidance receptor, homolog 2 (Drosophila) 1.245877 2.371626 0.001543
1390632_at BE107414 Rspo3 R-spondin 3 homolog (Xenopus laevis) 1.049128 2.069279 0.005955
1388356_at AI406499 S100a16 S100 calcium binding protein A16 1.404636 2.64751 0.00415
1368379_at NM_054001 Scarb2 Scavenger receptor class B, member 2 2.124624 4.360893 0.001346
1393338_at AW528719 Scx Scleraxis 1.644999 3.127476 0.007845
1368394_at AF140346 Sfrp4 Secreted frizzled-related protein 4 1.610004 3.052527 0.003747
1367802_at NM_019232 Sgk1 Serum/glucocorticoid regulated kinase 1 1.265947 2.404849 0.007546
1389779_at AA800626 Sh2d4a SH2 domain containing 4A 1.41792 2.672 0.032404
1392301_at AI237897 Sh3tc1 SH3 domain and tetratricopeptide repeats 1 1.214738 2.320987 0.006644
1392556_at BF410961 Shroom3 Shroom family member 3 1.454496 2.740607 9.57E-05
1376040_at BI290044 Sipa1l2 Signal-induced proliferation-associated 1 like 2 1.185619 2.274609 0.012637
1368565_at NM_019225 Slc1a3 Solute carrier family 1 (glial high affinity glutamate transporter), member 3 1.926317 3.800836 0.003174
1376165_at BE098153 Slc24a3 Solute carrier family 24 (sodium/potassium/calcium exchanger), member 3 1.145511 2.212244 0.000291
1398295_at NM_031684 Slc29a1 Solute carrier family 29 (nucleoside transporters), member 1 1.222426 2.333387 0.003869
1369074_at NM_130748 Slc38a4 Solute carrier family 38, member 4 2.25781 4.78265 0.00054
1392349_at BE116021 Slc5a3 Solute carrier family 5 (inositol transporters), member 3 1.031672 2.044392 0.000967
1387968_at L22022 Slc6a15 Solute carrier family 6 (neutral amino acid transporter), member 15 2.581534 5.985759 0.018733
1368920_at NM_031321 Slit3 Slit homolog 3 (Drosophila) 1.652522 3.143828 0.03084
1384437_at AI576309 Smarca1 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 1 1.83294 3.562623 4.14E-05
1377695_at BF281135 Smtnl2 Smoothelin-like 2 2.018633 4.051996 0.047065
1375349_at BI295776 Sorbs1 Sorbin and SH3 domain containing 1 2.508532 5.690409 0.000169
1372728_at BE103745 Sort1 Sortilin 1 1.319517 2.495825 0.006034
1371004_at AI070124 Sort1 Sortilin 1 1.117923 2.170343 0.00142
1379611_at BF416979 Spsb1 splA/ryanodine receptor domain and SOCS box containing 1 1.025012 2.034976 0.009283
1373554_at BE349698 Spsb1 splA/ryanodine receptor domain and SOCS box containing 1 1.010972 2.015269 0.008275
1389142_at AI013361 Sqrdl sulfide quinone reductase-like (yeast) 2.278473 4.851642 0.001121
1368109_at NM_031337 St3gal5 ST3 β-galactoside α-2,3-sialyltransferase 5 1.683094 3.211158 5.13E-05
1370907_at M83143 St6gal1 ST6 β-galactosamide α-2,6-sialyltranferase 1 1.294325 2.452622 0.000575
1389420_at BI279446 Stap2 Signal transducing adaptor family member 2 1.208781 2.311423 0.019358
1370680_at AF483620 Stau2 Staufen, RNA binding protein, homolog 2 (Drosophila) 1.015615 2.021764 0.000276
1372602_at BI295979 Stbd1 Starch binding domain 1 2.761499 6.781006 2.53E-05
1373590_at BI295949 Stom Stomatin 1.267382 2.407243 0.003323
1379732_at AW920037 Stx11 Syntaxin 11 1.976724 3.935983 9.77E-05
1368771_at NM_134378 Sulf1 Sulfatase 1 2.238326 4.718492 0.000659
1376572_a_at AI045848 Svil Supervillin 1.320708 2.497887 0.019303
1367570_at NM_031549 Tagln Transgelin 1.696733 3.24166 0.00228
1367859_at NM_013174 Tgfb3 Transforming growth factor, β 3 1.509832 2.847768 0.003273
1375951_at AA818521 Thbd Thrombomodulin 1.311404 2.481829 0.020049
1370474_at J03819 Thrb Thyroid hormone receptor β 2.219205 4.656368 0.002376
1387983_at J03933 Thrb Thyroid hormone receptor β 1.184729 2.273206 0.003624
1383623_at BM383909 Thyn1 Thymocyte nuclear protein 1 1.043826 2.061688 0.002044
1375138_at AA893169 Timp3 TIMP metallopeptidase inhibitor 3 6.264691 76.88826 0.015514
1389836_a_at AI599265 Timp3 TIMP metallopeptidase inhibitor 3 5.105264 34.42212 0.013029
1372926_at AI009159 Timp3 TIMP metallopeptidase inhibitor 3 4.004944 16.05492 0.025103
1368989_at NM_012886 Timp3 TIMP metallopeptidase inhibitor 3 2.253301 4.767725 0.015049
1373847_at AW435343 Tm4sf1 Transmembrane 4 L six family member 1 2.114633 4.330798 0.000242
1378305_at AI578087 Tm4sf1 Transmembrane 4 L six family member 1 1.938512 3.8331 0.000317
1390832_at BI294696 Tmcc3 Transmembrane and coiled-coil domain family 3 2.119391 4.345106 0.005139
1376623_at AI409186 Tmem204 Transmembrane protein 204 1.085094 2.121514 7.30E-05
1383314_at BE110098 Tmem51 Transmembrane protein 51 1.344562 2.539531 3.99E-05
1371361_at BI278826 Tns1 Tensin 1 1.158595 2.232399 0.000276
1370288_a_at AF372216 Tpm1 Tropomyosin 1, α 2.037181 4.104428 0.000937
1395794_at BF395218 Tpm1 Tropomyosin 1, α 1.997138 3.992073 0.008961
1371241_x_at AF370889 Tpm1 Tropomyosin 1, α 1.663566 3.167985 0.013541
1370287_a_at M23764 Tpm1 Tropomyosin 1, α 1.59074 3.012039 5.95E-05
1368724_a_at NM_019131 Tpm1 Tropomyosin 1, α 1.054891 2.077561 0.0189
1372219_at AA012755 Tpm2 Tropomyosin 2 1.064563 2.091537 2.16E-05
1398759_at NM_013043 Tsc22d1 TSC22 domain family, member 1 1.051368 2.072494 0.000844
1377630_at AI408602 Tspan13 Tetraspanin 13 1.481687 2.792752 0.019678
1375057_at BG377313 Tspan18 Tetraspanin 18 1.454071 2.739802 0.03087
1398476_at AW527349 Vcl Vinculin 1.244474 2.369321 0.000134
1372905_at AW433888 Vcl Vinculin 1.136321 2.198197 3.11E-05
1369098_at NM_013155 Vldlr Very low density lipoprotein receptor 1.505396 2.839027 0.001107
1387455_a_at NM_013155 Vldlr Very low density lipoprotein receptor 1.471028 2.772194 0.001621
1389611_at AA849857 Vldlr Very low density lipoprotein receptor 1.435945 2.705593 0.000947
1368854_at AI227991 Vsnl1 Visinin-like 1 2.472695 5.550796 0.007104
1368853_at NM_012686 Vsnl1 Visinin-like 1 2.077806 4.221647 0.004903
1387873_at BI279661 Wfdc1 WAP four-disulfide core domain 1 1.449292 2.730739 0.003744
1370221_at BF419320 Wisp1 WNT1 inducible signaling pathway protein 1 1.058567 2.082861 0.000154
1393613_at BE117871 Zfp462 Zinc finger protein 462 1.088387 2.126361 0.004351
1383462_at BF566263 Znf294 Zinc finger protein 294 1.010246 2.014255 0.000352

Supplementary Table 2.

Downregulated genes in miR-146a-transfected hepatic stellate cell-2

Probe ID Representative public ID Gene symbol Gene title Log2 Fold change P-value
1374345_at AI111707 -3.40046 -10.5594 1.80E-07
1397317_at BI296984 -3.25476 -9.54513 3.34E-07
1397400_at BM391846 -3.11991 -8.69335 5.36E-05
1382027_at BI296880 -3.05526 -8.31237 3.85E-07
1380245_at AI411847 -2.90249 -7.47715 8.46E-07
1381129_at BF392367 -2.52142 -5.74147 0.018162
1383211_at BE109736 -2.46677 -5.52805 0.006284
1380057_at BE097091 -2.33498 -5.04543 0.000685
1381048_at BF398435 -2.3159 -4.97916 0.000443
1381064_at AI137604 -2.26573 -4.80896 1.32E-07
1373583_at BF396317 -2.2618 -4.79589 1.23E-07
1377240_at AW526305 -2.19645 -4.58351 0.001977
1394468_at BF287020 -2.12335 -4.35705 0.000157
1377678_at BI283757 -2.12273 -4.35519 0.000117
1375101_at BI292651 -2.05823 -4.16476 0.000442
1380712_at AI406475 -2.04987 -4.14068 0.006175
1372110_at BE113148 -1.95331 -3.87261 0.000463
1394517_at AW522148 -1.88952 -3.70513 0.006671
1390530_at AI169239 -1.87482 -3.66755 0.00151
1376463_at AA955579 -1.87022 -3.65587 0.001028
1384743_at BF418132 -1.86231 -3.63589 2.42E-14
1377114_at AI410861 -1.8391 -3.57788 8.88E-06
1377161_at BG378317 -1.83484 -3.56731 0.039081
1383220_at BE114231 -1.73514 -3.32911 0.000179
1393143_at AI045866 -1.69968 -3.24828 0.005065
1376324_at BF406329 -1.68113 -3.20679 0.004765
1390429_at BF398114 -1.62771 -3.09021 6.83E-05
1382431_at AI103530 -1.6169 -3.06716 1.15E-06
1391251_at BI290666 -1.60415 -3.04016 1.73E-05
1383580_at AA859643 -1.58751 -3.0053 0.000305
1372011_at BI292028 -1.5749 -2.97915 0.000487
1377232_at BF406608 -1.54704 -2.92217 0.003334
1398457_at AI146156 -1.50417 -2.83662 0.005925
1381161_a_at BI301117 -1.47549 -2.78078 0.008417
1382142_at AI029975 -1.45644 -2.74431 3.98E-05
1382472_at AI502459 -1.44328 -2.71939 8.76E-05
1375266_at BG380633 -1.43613 -2.70595 0.010349
1381862_at AW524296 -1.39645 -2.63253 0.004828
1393235_at AI059968 -1.39173 -2.62392 0.000172
1385181_at AI029337 -1.39139 -2.62332 1.30E-07
1377686_at AA859337 -1.37593 -2.59535 3.53E-07
1372449_at AW253616 -1.37158 -2.58753 0.00912
1377556_at AW535380 -1.36924 -2.58334 0.004323
1372637_at AI169241 -1.36639 -2.57825 0.000419
1375957_at AW434654 -1.30351 -2.46828 4.46E-06
1383936_at BM386842 -1.29935 -2.46118 1.09E-05
1384724_at AA850766 -1.28208 -2.4319 3.20E-05
1379510_at BF546306 -1.20859 -2.31112 9.04E-05
1382296_at BF291041 -1.20836 -2.31075 1.53E-05
1382544_at AI058746 -1.20774 -2.30975 3.79E-06
1376816_at BF284903 -1.19854 -2.29507 0.000155
1383019_at BF558478 -1.18776 -2.27798 0.000454
1374558_at AI010316 -1.17751 -2.26186 8.04E-06
1389250_at AW915115 -1.16975 -2.24972 9.96E-05
1377328_at BI290012 -1.16378 -2.24044 0.009615
1380602_at AI764190 -1.16264 -2.23867 0.001006
1384812_at AI229409 -1.15815 -2.23172 0.006986
1396217_at BF542447 -1.1372 -2.19954 0.000345
1397668_at H34328 -1.13718 -2.1995 3.26E-07
1374932_at BI282731 -1.13055 -2.18943 0.001048
1385381_at AA996491 -1.12644 -2.1832 0.000161
1394047_at BE107848 -1.10947 -2.15767 0.035398
1397452_at AI112776 -1.10848 -2.15618 0.000172
1393730_at BI277836 -1.10819 -2.15575 0.03382
1381975_at BG371767 -1.10049 -2.14427 0.001469
1380699_at BE110761 -1.09332 -2.13364 0.000497
1374920_at AI228955 -1.07203 -2.10239 2.65E-05
1375473_at BI296644 -1.05345 -2.07548 0.001418
1373914_at BM389075 -1.05092 -2.07186 0.001887
1383436_at BG376768 -1.04917 -2.06933 0.000656
1390405_at AA942765 -1.0454 -2.06394 0.003275
1376911_at BM386385 -1.04165 -2.05858 0.000165
1384183_at AA996869 -1.03133 -2.04391 0.004095
1377469_at AI103161 -1.0216 -2.03016 0.006072
1393030_at BE115641 -1.01825 -2.02547 0.000652
1377113_at BF415786 -1.0168 -2.02343 0.002724
1382960_at BE108047 -1.01496 -2.02084 9.24E-05
1377955_at AI137602 -1.01226 -2.01707 4.55E-07
1391853_at AA998997 -1.00175 -2.00243 0.000388
1384086_at BG671196 -1.00024 -2.00033 0.031992
1385235_at AA818804 A2bp1 Ataxin 2 binding protein 1 -1.24533 -2.37073 4.71E-05
1383130_at BF555795 A2bp1 Ataxin 2 binding protein 1 -1.07712 -2.10983 0.000947
1394490_at AI502114 Abca1 ATP-binding cassette, sub-family A (ABC1), member 1 -1.80354 -3.49076 3.72E-07
1384381_at BF284523 Abca1 ATP-binding cassette, sub-family A (ABC1), member 1 -1.27132 -2.41382 0.000215
1383355_at AW918387 Abca1 ATP-binding cassette, sub-family A (ABC1), member 1 -1.21129 -2.31545 5.71E-07
1369928_at NM_019212 Acta1 Actin, α 1, skeletal muscle -3.10676 -8.61449 4.42E-05
1370856_at AA800705 Actc1 Actin, α, cardiac muscle 1 -1.26863 -2.40933 2.02E-05
1394483_at AW535310 Adamts5 ADAM metallopeptidase with thrombospondin type 1 motif, 5 -1.53094 -2.88975 1.96E-05
1390383_at BI285616 Adfp Adipose differentiation related protein -2.49834 -5.65037 3.30E-08
1382680_at BG673602 Adfp Adipose differentiation related protein -2.22186 -4.66496 1.20E-05
1387395_at NM_017161 Adora2b Adenosine A2B receptor -2.08666 -4.24763 0.000258
1395695_at BE126420 Aebp1 AE binding protein 1 -1.5972 -3.02555 0.005916
1372301_at BI278482 Aebp1 AE binding protein 1 -1.55735 -2.94313 0.01167
1368342_at NM_031544 Ampd3 Adenosine monophosphate deaminase 3 -1.65434 -3.14779 0.004546
1377783_at BI294141 Angpt4 Angiopoietin 4 -1.64644 -3.1306 0.001964
1397579_x_at BI294552 Apc2 Adenomatosis polyposis coli 2 -1.91631 -3.77455 0.00151
1395461_at BI294552 Apc2 Adenomatosis polyposis coli 2 -1.30834 -2.47656 0.002146
1391083_at BM384457 Arhgap22 Rho GTPase activating protein 22 -1.09826 -2.14096 0.007774
1377385_at BE100015 Arhgap27 Rho GTPase activating protein 27 -1.30775 -2.47556 6.57E-07
1387959_at AB009372 Aspg Asparaginase homolog (S. cerevisiae) -1.29918 -2.46089 0.000534
1380726_at BI290633 Aspn Asporin -2.13124 -4.38092 0.032454
1381504_at AI639412 Aspn Asporin -1.90669 -3.74947 0.02918
1368477_at NM_012914 Atp2a3 ATPase, Ca++ transporting, ubiquitous -1.60464 -3.04119 0.000593
1369664_at NM_053019 Avpr1a Arginine vasopressin receptor 1A -2.07931 -4.22605 1.62E-05
1375941_at BI292120 Baiap2l1 BAI1-associated protein 2-like 1 -1.64069 -3.11816 1.70E-06
1369807_at NM_030851 Bdkrb1 Bradykinin receptor B1 -1.11926 -2.17236 0.000155
1391345_at BI293047 Bmper BMP-binding endothelial regulator -1.85131 -3.60828 3.59E-06
1387540_at NM_012514 Brca1 Breast cancer 1 -1.02475 -2.03461 0.000898
1381995_at AW530502 Brunol4 Bruno-like 4, RNA binding protein (Drosophila) -2.20211 -4.60152 7.21E-08
1387893_at D88250 C1s Complement component 1, s subcomponent -1.26395 -2.40152 0.048179
1375569_at BM386267 Ccdc92 Coiled-coil domain containing 92 -1.03224 -2.0452 0.000197
1367973_at NM_031530 Ccl2 Chemokine (C-C motif) ligand 2 -2.02826 -4.07912 0.002595
1379935_at BF419899 Ccl7 Chemokine (C-C motif) ligand 7 -1.07909 -2.11271 0.006482
1370810_at L09752 Ccnd2 Cyclin D2 -1.31667 -2.49091 0.005098
1389490_at BI274335 Cd248 CD248 molecule, endosialin -3.64068 -12.4725 1.26E-06
1389755_at BM391858 Cdca7l Cell division cycle associated 7 like -1.4418 -2.71661 0.000141
1369425_at NM_138889 Cdh13 Cadherin 13 -3.4441 -10.8837 4.56E-08
1375719_s_at BG381748 Cdh13 Cadherin 13 -3.2068 -9.23301 2.00E-08
1373102_at BI282750 Cdh13 Cadherin 13 -3.03097 -8.1736 6.92E-06
1373054_at AA801076 Cdw92 CDW92 antigen -1.00321 -2.00445 0.000362
1396034_at BF402373 Ces7 Carboxylesterase 7 -2.24147 -4.72879 7.58E-05
1389179_at BF284899 Cidea Cell death-inducing DNA fragmentation factor, α subunit-like effector A -1.13966 -2.20329 1.12E-05
1367740_at M14400 Ckb Creatine kinase, brain -1.40456 -2.64738 0.000293
1392672_at AI576758 Clec11a C-type lectin domain family 11, member a -1.45028 -2.73262 0.004619
1368571_at NM_021997 Clip2 CAP-GLY domain containing linker protein 2 -1.09569 -2.13715 4.77E-07
1372584_at BG672517 Cnrip1 Cannabinoid receptor interacting protein 1 -1.11448 -2.16517 1.59E-08
1379345_at BM386752 Col15a1 Collagen, type XV, α 1 -6.09695 -68.4485 3.18E-06
1388939_at AA800298 Col15a1 Collagen, type XV, α 1 -4.48588 -22.4071 2.71E-05
1384969_at BE109107 Col24a1 Collagen, type XXIV, α 1 -1.8271 -3.54824 0.002725
1371349_at AI598402 Col6a1 Collagen, type VI, α 1 -1.66097 -3.16228 0.001251
1371369_at BI287851 Col6a2 Collagen, type VI, α 2 -1.80919 -3.50445 9.31E-05
1372818_at BI284441 Colec12 Collectin sub-family member 12 -2.38156 -5.211 3.25E-07
1372774_at AI170570 Coq6 Coenzyme Q6 homolog (yeast) -1.57329 -2.97583 1.94E-06
1369964_at NM_130411 Coro1a Coronin, actin binding protein 1A -1.6641 -3.16916 7.57E-05
1392996_at BG668435 Cpeb1 Cytoplasmic polyadenylation element binding protein 1 -1.42707 -2.68901 3.55E-05
1368293_at NM_031766 Cpz Carboxypeptidase Z -1.17127 -2.2521 0.020505
1376051_at BI293393 Cryl1 Crystallin, lambda 1 -2.8568 -7.24406 4.30E-05
1383575_at BG376561 Ctnnd2 Catenin (cadherin-associated protein), delta 2 (neural plakophilin-related arm-repeat protein) -2.38434 -5.22105 9.56E-05
1369947_at NM_031560 Ctsk Cathepsin K -1.00677 -2.00941 0.001608
1387969_at U22520 Cxcl10 Chemokine (C-X-C motif) ligand 10 -2.22859 -4.68674 4.90E-05
1368738_at D11354 Cyp11b1 Cytochrome P450, subfamily 11B, polypeptide 1 -1.731 -3.31958 0.003738
1387305_s_at NM_012539 Cyp11b1 /// Cyp11b2 Cytochrome P450, subfamily 11B, polypeptide 1 /// cytochrome P450, subfamily 11B, polypeptide 2 -1.73027 -3.3179 4.54E-05
1387276_at NM_021584 Dclk1 Doublecortin-like kinase 1 -1.05016 -2.07076 0.000907
1384971_at BI289108 Depdc7 DEP domain containing 7 -1.10481 -2.1507 0.000468
1371732_at BI285485 Dpt Dermatopontin -1.89757 -3.72585 0.009977
1383853_at BE103067 Dyrk3 Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 3 -1.76949 -3.40934 1.66E-07
1383641_at BF414702 Ednra Endothelin receptor type A -2.19922 -4.5923 0.01467
1378342_at BF284819 Ednra Endothelin receptor type A -1.78129 -3.43733 0.004867
1393415_at BF548891 Ednra Endothelin receptor type A -1.51332 -2.85467 0.00743
1391442_at AA957585 Ehd3 EH-domain containing 3 -1.71662 -3.28665 3.90E-05
1367905_at NM_019370 Enpp3 Ectonucleotide pyrophosphatase/phosphodiesterase 3 -1.33397 -2.52096 9.07E-05
1382434_at AI059015 Entpd5 Ectonucleoside triphosphate diphosphohydrolase 5 -1.63931 -3.11518 2.50E-06
1370503_s_at AB032828 Epb4.1l3 Erythrocyte protein band 4.1-like 3 -1.9425 -3.84372 0.005443
1368515_at NM_053927 Epb4.1l3 Erythrocyte protein band 4.1-like 3 -1.52656 -2.88098 0.000173
1369422_at NM_138850 Fap Fibroblast activation protein, α -1.69721 -3.24274 0.001039
1376561_at AW523739 Fbxo16 F-box protein 16 -1.11142 -2.16058 6.95E-06
1367850_at NM_053843 Fcgr2a /// LOC498276 /// LOC498277 Fc fragment of IgG, low affinity IIa, receptor (CD32) /// Fc γ receptor II β /// similar to Low affinity immunoglobulin γ Fc region receptor III precursor (IgG Fc receptor III) (Fc-γ RIII) (FcRIII) -1.23098 -2.34726 0.007866
1392865_at BG371594 Fgf9 Fibroblast growth factor 9 -2.37371 -5.18274 0.002748
1373882_at AI170324 Figf C-fos induced growth factor -2.48251 -5.58869 0.000198
1387709_at AY032728 Figf C-fos induced growth factor -2.21994 -4.65873 5.44E-07
1374726_at AI411941 Fndc1 Fibronectin type III domain containing 1 -2.18189 -4.53749 0.005581
1370248_at AA851939 Fxyd6 FXYD domain-containing ion transport regulator 6 -1.91583 -3.77331 0.004165
1385636_at AI029226 Fzd3 Frizzled homolog 3 (Drosophila) -1.30152 -2.46488 6.39E-06
1388395_at AI406939 G0s2 G0/G1switch 2 -1.69782 -3.2441 6.68E-05
1382314_at BE096523 G1p2 Interferon, α-inducible protein (clone IFI-15K) -1.43064 -2.69565 0.012403
1370963_at AJ131902 Gas7 Growth arrest specific 7 -2.12746 -4.36946 0.001866
1387221_at NM_024356 Gch1 GTP cyclohydrolase 1 -1.0345 -2.0484 0.001025
1368085_at NM_133595 Gchfr GTP cyclohydrolase I feedback regulator -1.09278 -2.13284 1.23E-05
1368770_at NM_022276 Gcnt1 Glucosaminyl (N-acetyl) transferase 1, core 2 -1.35748 -2.56237 0.000674
1387659_at AF245172 Gda Guanine deaminase -1.54413 -2.91629 0.000209
1377761_at BI296057 Gfpt2 Glutamine-fructose-6-phosphate transaminase 2 -2.3887 -5.23685 0.003422
1387007_at NM_012959 Gfra1 GDNF family receptor α 1 -1.49726 -2.82306 0.000202
1367954_at U59486 Gfra1 GDNF family receptor α 1 -1.10817 -2.15573 0.0006
1397461_at BF416400 Glt8d2 Glycosyltransferase 8 domain containing 2 -1.11036 -2.15899 8.28E-06
1386870_at BI275294 Glul Glutamate-ammonia ligase (glutamine synthetase) -1.18385 -2.27182 0.000113
1367632_at NM_017073 Glul Glutamate-ammonia ligase (glutamine synthetase) -1.11961 -2.17288 0.003082
1369302_at NM_133573 Gper G protein-coupled estrogen receptor 1 -1.10018 -2.14381 0.001057
1387241_at NM_031696 Gpr88 G-protein coupled receptor 88 -1.11226 -2.16184 0.002865
1369926_at NM_022525 Gpx3 Glutathione peroxidase 3 -2.05946 -4.16829 1.35E-06
1374488_at AI175700 Gramd1b GRAM domain containing 1B -1.12881 -2.18678 0.001788
1368180_s_at NM_017013 Gsta2 /// LOC494499 Glutathione S-transferase A2 /// LOC494499 protein -2.31111 -4.96266 6.68E-05
1371298_at BF284168 H19 H19 fetal liver mRNA -1.87119 -3.65833 0.000303
1391575_at BG380566 Hapln4 Hyaluronan and proteoglycan link protein 4 -1.12321 -2.17831 0.002326
1368255_at NM_017354 Hnt Neurotrimin -2.33813 -5.05648 0.0043
1367816_at NM_133621 Hopx HOP homeobox -1.32323 -2.50226 0.003008
1393592_at AA998087 Hs3st5 Heparan sulfate (glucosamine) 3-O-sulfotransferase 5 -1.19206 -2.28479 0.004675
1368578_at NM_017265 Hsd3b1 Hydroxy-delta-5-steroid dehydrogenase, 3 β- and steroid delta-isomerase 1 -2.132 -4.38324 0.00025
1387282_at NM_053612 Hspb8 Heat shock protein 8 -1.47457 -2.77901 2.14E-07
1388721_at BG380282 Hspb8 Heat shock protein 8 -1.28154 -2.43098 1.12E-06
1376908_at AW531805 Ifit3 Interferon-induced protein with tetratricopeptide repeats 3 -1.35357 -2.55544 0.019235
1382220_at AI180454 Igf2bp2 Insulin-like growth factor 2 mRNA binding protein 2 -1.40203 -2.64272 0.00737
1387180_at NM_053953 Il1r2 Interleukin 1 receptor, type II -2.39783 -5.27012 0.000126
1387273_at NM_013037 Il1rl1 Interleukin 1 receptor-like 1 -3.65216 -12.5721 0.013461
1370692_at U04317 Il1rl1 Interleukin 1 receptor-like 1 -1.22822 -2.34278 0.004082
1387504_at NM_133575 Il1rl2 Interleukin 1 receptor-like 2 -1.5258 -2.87946 7.08E-05
1377163_at BM385741 Inhbb Inhibin β-B -1.23015 -2.34591 0.014339
1369043_at NM_012971 Kcna4 Potassium voltage-gated channel, shaker-related subfamily, member 4 -4.1772 -18.091 8.01E-08
1390404_at BF556962 Lama2 Laminin, α 2 -2.54141 -5.82159 9.68E-05
1370138_at NM_130429 Lef1 Lymphoid enhancer binding factor 1 -1.10908 -2.15708 0.000657
1378179_a_at AW524864 Lhfpl2 Lipoma HMGIC fusion partner-like 2 -1.03801 -2.05339 0.00217
1371094_at L06804 Lhx2 LIM homeobox 2 -1.06797 -2.09648 0.000653
1389885_at BI294855 Limd2 LIM domain containing 2 -1.05098 -2.07194 6.73E-05
1376871_at AA891475 LOC680910 /// LOC681069 /// LOC681182 /// LOC681196 /// LOC685030 /// LOC685048 /// LOC685111 /// LOC685262 /// LOC685305 /// LOC686848 /// LOC686899 /// RGD1559588 /// RGD1561143 /// RGD1561730 /// RGD1562525 /// RGD1563400 /// RGD1566006 Similar to paired immunoglobin-like type 2 receptor β /// similar to paired immunoglobin-like type 2 receptor β /// similar to paired immunoglobin-like type 2 receptor β /// similar to paired immunoglobin-like type 2 receptor β /// similar to paired immunoglobin-like type 2 receptor β /// similar to paired immunoglobin-like type 2 receptor β /// similar to paired immunoglobin-like type 2 receptor β /// similar to paired immunoglobin-like type 2 receptor β /// similar to paired immunoglobin-like type 2 receptor β /// similar to paired immunoglobin-like type 2 receptor β /// similar to paired immunoglobin-like type 2 receptor β /// similar to cell surface receptor FDFACT /// similar to cell surface receptor FDFACT /// similar to cell surface receptor FDFACT /// similar to cell surface receptor FDFACT /// similar to paired immunoglobin-like type 2 receptor β /// similar to paired immunoglobin-like type 2 receptor β -1.06939 -2.09855 2.14E-06
1385047_x_at AI012782 LOC685048 /// LOC685111 /// RGD1559588 /// Vom2r61 Similar to paired immunoglobin-like type 2 receptor β /// similar to paired immunoglobin-like type 2 receptor β /// similar to cell surface receptor FDFACT /// vomeronasal 2 receptor, 61 -2.82049 -7.064 5.90E-06
1393688_at AI012782 LOC685048 /// LOC685111 /// RGD1559588 /// Vom2r61 Similar to paired immunoglobin-like type 2 receptor β /// similar to paired immunoglobin-like type 2 receptor β /// similar to cell surface receptor FDFACT /// vomeronasal 2 receptor, 61 -2.75933 -6.7708 2.26E-07
1371293_at AI103218 LOC688228 Similar to Myosin light polypeptide 4 (Myosin light chain 1, atrial isoform) -1.30459 -2.47013 6.68E-07
1398732_at BF553297 LOC688273 Hypothetical protein LOC688273 -3.37961 -10.4079 0.000276
1384540_at BE101066 Lrfn3 Leucine rich repeat and fibronectin type III domain containing 3 -1.05498 -2.07769 0.00043
1388347_at AI233210 Ly6e Lymphocyte antigen 6 complex, locus E -2.7688 -6.81539 1.82E-05
1376184_at BG381127 Lynx1 Ly6/neurotoxin 1 -1.98858 -3.96846 8.46E-08
1393645_at BI288003 Mageb16 Melanoma antigen family B, 16 -1.53459 -2.89706 0.000131
1388152_at BG374290 Map2 Microtubule-associated protein 2 -1.7733 -3.41836 0.008563
1382046_at AA963495 Map3k3 Mitogen activated protein kinase kinase kinase 3 -1.24191 -2.36511 1.42E-06
1392547_at AI716211 MGC105649 Hypothetical LOC302884 -2.31654 -4.98136 0.004157
1388300_at AA892234 Mgst3 Microsomal glutathione S-transferase 3 -1.007 -2.00973 0.017898
1393836_at BE097933 Mitf Microphthalmia-associated transcription factor -1.0956 -2.13702 0.010323
1368590_at NM_080776 Mmp16 Matrix metallopeptidase 16 -1.01729 -2.02411 0.000829
1370301_at U65656 Mmp2 Matrix metallopeptidase 2 -3.98031 -15.7831 0.000568
1382190_at BF405725 Mrgprf MAS-related GPR, member F -3.60572 -12.1739 3.94E-07
1368441_at NM_031658 Msln Mesothelin -1.36403 -2.57403 0.001477
1376648_at BI275570 Mycn V-myc myelocytomatosis viral related oncogene, neuroblastoma derived (avian) -1.62357 -3.08136 0.002089
1368415_at NM_012604 Myh3 Myosin, heavy chain 3, skeletal muscle, embryonic -1.24039 -2.36262 0.003414
1387787_at NM_012605 Mylpf Myosin light chain, phosphorylatable, fast skeletal muscle -2.12252 -4.35453 0.000567
1398655_at AA955902 Myod1 Myogenic differentiation 1 -2.39143 -5.24677 9.65E-05
1373839_at BG372386 Nope Neighbor of Punc E11 -1.24338 -2.36752 0.009522
1371036_at BG671431 Nrcam Neuronal cell adhesion molecule -1.60969 -3.05187 2.40E-06
1384112_at BI289470 Nt5e 5' nucleotidase, ecto -1.1205 -2.17423 0.004069
1392780_at BF283270 Nxf7 nuclear RNA export factor 7 -3.39721 -10.5357 0.005424
1377497_at BF419319 Oasl 2'-5'-oligoadenylate synthetase-like -1.36533 -2.57636 2.34E-05
1369008_a_at NM_053573 Olfm1 Olfactomedin 1 -3.58878 -12.0318 0.000169
1368940_at NM_017255 P2ry2 Purinergic receptor P2Y, G-protein coupled 2 -1.21116 -2.31523 0.009814
1383273_a_at AA956005 Pcbp3 Poly(rC) binding protein 3 -2.10678 -4.30729 4.21E-06
1383274_at AA956005 Pcbp3 Poly(rC) binding protein 3 -1.8662 -3.64572 0.000552
1385116_at BF386807 Pcdhb21 Protocadherin β 21 -1.13304 -2.19321 0.007625
1373368_at BI279680 PCOLCE2 Procollagen C-endopeptidase enhancer 2 -1.805 -3.4943 7.61E-07
1368145_at NM_013002 Pcp4 Purkinje cell protein 4 -4.28374 -19.4775 0.000401
1370941_at AI232379 Pdgfra Platelet derived growth factor receptor, α polypeptide -1.62538 -3.08523 0.011837
1377100_at AI172172 Pds5b PDS5, regulator of cohesion maintenance, homolog B (S. cerevisiae) -1.14971 -2.21869 1.40E-05
1388634_at BI277505 Pgm1 Phosphoglucomutase 1 -1.66935 -3.18071 9.06E-09
1369473_at NM_017033 Pgm1 Phosphoglucomutase 1 -1.50694 -2.84207 3.02E-06
1383749_at AI112954 Phospho1 Phosphatase, orphan 1 -1.16307 -2.23934 0.003657
1370445_at D88666 Pla1a Phospholipase A1 member A -1.35014 -2.54937 0.001836
1390190_at BI293691 Plac1 Placenta-specific 1 -2.19087 -4.56582 0.000174
1384558_at BI276313 Plac9 Placenta-specific 9 -1.07069 -2.10043 0.007797
1367800_at NM_013151 Plat Plasminogen activator, tissue -1.15024 -2.21951 0.004677
1391187_at BI303019 Ppl Periplakin -1.11393 -2.16434 0.000262
1368259_at NM_017043 Ptgs1 Prostaglandin-endoperoxide synthase 1 -2.42323 -5.3637 3.32E-05
1381806_at BF418208 Ptgs1 Prostaglandin-endoperoxide synthase 1 -1.06169 -2.08737 5.08E-05
1372084_at AI104546 Ptp4a3 Protein tyrosine phosphatase 4a3 -1.0212 -2.02961 2.54E-05
1368350_at NM_013080 Ptprz1 Protein tyrosine phosphatase, receptor-type, Z polypeptide 1 -1.04165 -2.05858 0.022268
1373646_at BM384841 Rab15 RAB15, member RAS oncogene family -1.17275 -2.2544 7.21E-05
1374035_at BI296482 Rem2 RAS (RAD and GEM) like GTP binding 2 -1.00521 -2.00723 0.017185
1368080_at NM_054008 Rgc32 Response gene to complement 32 -1.00087 -2.00121 0.032818
1392883_at AI013730 RGD1305269 Similar to hypothetical protein -1.04588 -2.06463 1.81E-05
1373226_at BF400995 RGD1308019 Similar to hypothetical protein FLJ20245 -1.10844 -2.15613 0.015649
1381757_at AA965058 RGD1309501 Hypothetical LOC305552 -1.28517 -2.43712 2.17E-05
1373596_at AI230766 RGD1310423 Similar to hypothetical protein FLJ31737 -2.01177 -4.03277 6.86E-08
1398577_at BI297744 RGD1310507 Similar to RIKEN cDNA 1300017J02 -1.72535 -3.30661 0.000821
1390397_at BF413152 RGD1310753 Similar to chromosome 20 open reading frame 39 -2.10856 -4.31261 5.11E-05
1393191_at BF554733 RGD1561205 Similar to RIKEN cDNA 2610200G18 -1.39361 -2.62736 0.000183
1376693_at AA998964 RGD1563091 Similar to OEF2 -1.00045 -2.00063 0.047169
1395145_at BF544481 Rgl1 Ral guanine nucleotide dissociation stimulator,-like 1 -1.5473 -2.9227 0.000329
1394472_at BF282814 Rgl1 Ral guanine nucleotide dissociation stimulator,-like 1 -1.20268 -2.30166 0.005425
1391075_at AI179271 Rgs17 Regulator of G-protein signaling 17 -1.50436 -2.83699 0.004883
1368373_at NM_019343 Rgs7 Regulator of G-protein signaling 7 -3.29254 -9.79836 1.82E-05
1370142_at NM_022175 Rhox5 Reproductive homeobox 5 -3.12793 -8.74178 2.44E-09
1383554_at AW142796 Rnf128 Ring finger protein 128 -1.473 -2.77598 1.47E-05
1389735_at BE107296 Rps6ka6 Ribosomal protein S6 kinase polypeptide 6 -1.18452 -2.27288 0.013943
1384707_at AI600020 Scara5 Scavenger receptor class A, member 5 (putative) -1.46379 -2.75833 9.19E-06
1392856_at AI549470 Serf1 Small EDRK-rich factor 1 -1.52508 -2.87802 0.00071
1375084_at BF419780 Serinc2 Serine incorporator 2 -1.64207 -3.12113 0.000591
1377034_at BF411331 Serpinb1a Serine (or cysteine) proteinase inhibitor, clade B, member 1a -1.17504 -2.25799 8.45E-05
1369547_at NM_130404 Serpinb7 Serine (or cysteine) peptidase inhibitor, clade B, member 7 -1.4094 -2.65626 0.001746
1393620_at AI113325 Sesn3 Sestrin 3 -1.17758 -2.26198 0.001718
1390119_at BF396602 Sfrp2 Secreted frizzled-related protein 2 -1.64679 -3.13135 0.011642
1367881_at NM_013016 Sirpa Signal-regulatory protein α -1.88267 -3.68756 1.79E-06
1392789_at BI296353 Slc25a36 Solute carrier family 25, member 36 -2.25714 -4.78042 4.14E-05
1372341_at AI233213 Slc25a36 Solute carrier family 25, member 36 -2.07958 -4.22685 0.000633
1369237_at NM_053996 Slc6a7 Solute carrier family 6 (neurotransmitter transporter, L-proline), member 7 -1.12269 -2.17753 0.00114
1368322_at NM_012880 Sod3 Superoxide dismutase 3, extracellular -2.20485 -4.61028 1.15E-05
1368254_a_at AB049572 Sphk1 Sphingosine kinase 1 -1.09627 -2.13802 0.00473
1368655_at NM_020074 Srgn Serglycin -2.51283 -5.70737 0.006656
1373146_at AI716240 Ssx2ip Synovial sarcoma, X breakpoint 2 interacting protein -1.23239 -2.34956 0.001168
1387174_a_at AB006007 Star Steroidogenic acute regulatory protein -3.29954 -9.84599 0.000194
1368406_at NM_031558 Star Steroidogenic acute regulatory protein -2.92085 -7.57291 7.29E-07
1377672_at BI300997 Sult1c2 Sulfotransferase family, cytosolic, 1C, member 2 -3.45192 -10.9429 3.19E-06
1369531_at NM_133547 Sult1c2 Sulfotransferase family, cytosolic, 1C, member 2 -2.77927 -6.86504 2.07E-05
1369627_at L10362 Sv2b Synaptic vesicle glycoprotein 2b -2.39744 -5.26866 0.000178
1385637_at AI029494 Svep1 Sushi, von Willebrand factor type A, EGF and pentraxin domain containing 1 -1.08524 -2.12172 0.000482
1383686_at BE111537 Syngr1 Synaptogyrin 1 -1.73204 -3.32197 0.00524
1384202_at BI287326 Tesc Tescalcin -1.69209 -3.23124 0.004681
1371913_at BG379319 Tgfbi Transforming growth factor, β induced -1.05453 -2.07704 0.023537
1369652_at AI145313 Thy1 Thy-1 cell surface antigen -3.93458 -15.2907 2.03E-07
1369651_at NM_012673 Thy1 Thy-1 cell surface antigen -3.67268 -12.7522 7.68E-08
1392980_at AI716456 Tiam1 T-cell lymphoma invasion and metastasis 1 -1.56449 -2.95774 7.40E-06
1382222_at BI293607 Tmem163 Transmembrane protein 163 -2.1182 -4.34153 8.73E-06
1376106_at AI010157 Tmem178 Transmembrane protein 178 -3.28823 -9.76912 0.007054
1377554_at BF394106 Tnfsf9 Tumor necrosis factor (ligand) superfamily, member 9 -1.95931 -3.88877 1.88E-05
1370332_at AF159356 Unc13d Unc-13 homolog D (C. elegans) -2.36452 -5.1498 0.000313
1368474_at NM_012889 Vcam1 Vascular cell adhesion molecule 1 -3.24587 -9.48643 1.90E-05
1388142_at AA850991 Vcan Versican -1.54149 -2.91096 0.000288
1388054_a_at AF072892 Vcan Versican -1.53261 -2.89308 0.000536
1371232_a_at AF084544 Vcan Versican -1.47614 -2.78204 0.000764
1388265_x_at AF084544 Vcan Versican -1.45114 -2.73423 0.001864
1389253_at BI289085 Vnn1 Vanin 1 -1.15392 -2.22518 0.000172
1382283_at BF283711 Wipf1 WAS/WASL interacting protein family, member 1 -1.01562 -2.02176 3.13E-05
1387227_at NM_057192 Wipf1 WAS/WASL interacting protein family, member 1 -1.00508 -2.00706 8.16E-05
1389119_at AI105018 Xirp1 Xin actin-binding repeat containing 1 -1.17137 -2.25226 9.90E-05
1372989_at BI296586 Zdhhc14 Zinc finger, DHHC-type containing 14 -3.38007 -10.4112 1.23E-07

We further analyzed the pathways which were significantly enriched, using a P value ≤ 0.05 as a threshold. Here, we observed enrichment for signaling pathways like integrin-linked kinase, hepatic fibrosis/HSC activation and caveolar-mediated endocytosis, calcium, cAMP-mediated signaling, integrin, endothelin-1 for the upregulated genes (Figure 7A), and hepatic fibrosis/HSC activation, lipopolysaccharide (LPS)/IL-1-mediated inhibition of retinoid X receptor (RXR) function and nitrogen metabolism, and liver X receptor/RXR activation for the downregulated genes (Figure 7B).

Figure 7.

Figure 7

Pathway analysis for the differentially expressed genes of miR-146a over-expressing clones. The charts depict the pathways affected by the (A) or (B) of genes upon stable transfection of miR-146a into hepatic stellate cell-2 cells. Only pathways with P ≤ 0.05 are shown. ILK: Integrin-linked kinase; FGF: Fibroblast growth factor; IL: Interleukin; LPS: Lipopolysaccharide; LXR: Liver X receptor; RXR: Retinoid X receptor.

The most interesting finding was the robust upregulation of TIMP-3 mRNA (Supplementary Tables 1), verified by real-time PCR (Figure 8A), which is an inhibitor of the tumor necrosis factor-α converting enzyme[22], and has been proposed as a tumor suppressor. Similarly, pHSCs treated with miR-146a mimic also showed induction of TIMP-3 mRNA (Figure 8B).

Figure 8.

Figure 8

Relative expression of tissue inhibitor of metalloproteinase-3 mRNA in rno-miR-146a-overexpressing hepatic stellate cell-2 cells. A: The graph depicts the relative changes in tissue inhibitor of metalloproteinase (TIMP)-3 mRNA of three rno-miR-146a-overexpressing clones detected by real-time polymerase chain reaction (PCR). The data represent the mean ± SE of two different passages for each clone (aP ≤ 0.005); B: Primary hepatic stellate cells were treated with 50 nmol/L miR-146a mimic, and the expression of TIMP-3 mRNA was analyzed by real-time PCR and expressed as fold change relative to mock controls. The data represent the mean ± SE of three independent experiments (bP ≤ 0.01). HSC: Hepatic stellate cell.

Time-dependent expression of different miRNAs during in vitro activation of pHSCs

The fact that miR-146a was not downregulated in in vivo activated pHSCs (CDE diet) prompted us to study the time-dependent expression of this miRNA during the in vitro activation of pHSCs, together with miR-26a, 29a and 214. The expression of miR-146a was indeed downregulated at day 3 already, and recovered subsequently until day 10. Although the miR-146a level at day 10 was still lower than that in quiescent pHSCs at day 0, there was still a 10-fold increase between day 3 and 10 (Figure 9A). In contrast, the expression of miR-26a and 29a did not change as dramatically from day 3 to day 10. We also noticed that miR-214 started to increase only from day 5 onwards (Figure 9A).

Figure 9.

Figure 9

Time-dependent changes in the expression of different miRNAs during in vitro activation and miRNA mimic and inhibitor transfection of primary hepatic stellate cells. A: The relative changes in the expression level after 3, 5, 7 and 10 d of in vitro primary hepatic stellate cells (pHSCs) activation is shown for miR-146a, 26a, 29a and 214 (aP ≤ 0.05, one-way ANOVA). The data represent one of two independent experiments performed in triplicate; B: pHSCs were transfected with miR-146a, 26a, 29a mimics or miR-214 inhibitor or in combination. The control transfection consisted of control miRNAs for the mimic and/or inhibitor. The smooth muscle α-actin and ColI mRNA expression was analyzed as fold change relative to mock controls. The data represent the mean ± SE of two independent experiments, each performed in triplicate (aP ≤ 0.05, bP ≤ 0.01, cP ≤ 0.001). SMAA: Smooth muscle α-actin.

Regulation of SMAA and ColI transcripts in pHSCs by different miRNA mimics and inhibitor

In order to study the effect of different miRNA mimics or inhibitor on the in vitro activation process, we transfected 3-d in vitro activated pHSCs for 3 d with miR-146a, 26a, 29a mimics, miR-214 hairpin inhibitor or all combined. The impact on the HSC activation was followed using real-time PCR to study the changes on the mRNA levels of SMAA and ColI. The high efficiency of transfection was demonstrated by real-time PCR (Figure 10). We found moderate upregulation of the activation marker SMAA by miR-146a (Figure 9B); an observation seen also for the miR-146a-overexpressing clones (Figure 5E and cDNA microarray data). In fact, all cells transfected with the mimics, the inhibitor or combined showed an upwards trend for SMAA mRNA compared to the mock control, although the level did not always change significantly (Figure 9B). For the ColI expression, we noted again an increase caused by miR-146a mimic (not significant) and a decrease by miR-26a, 29a mimic and miR-214 inhibitor. The quadruple transfection led to a suppression of ColI mRNA (Figure 9B).

Figure 10.

Figure 10

Transfection of primary hepatic stellate cells with different miRNA mimics and inhibitor. The miRNA expression was analyzed as fold change relative to mock transfected primary hepatic stellate cells (pHSCs). Shown are data for the transfection of miR-146a mimic and miR-214 inhibitor with respective control (A), for the transfection of miR-26a and miR-29a mimic with respective control (B) and for the quadruple transfection of miR-146a, miR-26a, miR-29a mimic and miR-214 inhibitor (C) (aP ≤ 0.05, bP ≤ 0.005).

DISCUSSION

The aim of this study was to gain a deeper insight into the regulation of miRNAs during the activation process of pHSCs, as well as the influence of up- or downregulation of miRNAs on the gene expression and activation of HSCs.

The expression analysis of miRNAs between quiescent and in vitro activated pHSCs yielded a number of induced and suppressed miRNAs (Table 1), some of which (miR-143, 16, 122, 146a, 92b, 126) confirmed the findings of Guo et al[23]. On the other hand, there were some differences in the regulation of certain miRNAs (miR-328, 207), which could be attributed to the dynamic nature of miRNA regulation and the different use of quiescent pHSCs (day 0 vs day 2).

When evaluating the miRNAs expression profile of the in vitro and in vivo activated pHSCs, a clear distinction was seen in the expression of miR-16, 26a, 29a, 125b, 146a and 150 (compare Figure 3A and B); a phenomenon which could be explained by the distinct HSC activation process. This has been shown at the gene expression level by De Minicis et al[24]. The in vivo activation was performed over a period of 4 wk, whereas the in vitro activation was monitored over 10 d, which could also account for some differences in the miRNA expression, assuming a dynamic regulation.

On the other hand, we found that certain miRNAs (let-7b, 7c and miR-214) were regulated in the same way during in vitro and in vivo activation of pHSCs. It also became clear to us that miR-214 could be a potential candidate for a diagnostic approach, because this miRNA always shows robust upregulation.

Pathway analysis of the miRNA microarray data was performed to obtain information on signaling cascades involving predicted targets of the differentially regulated miRNAs in in vitro activated pHSCs (Figure 4A and B). NO and ROS are known to play a role in the activation process and apoptosis of HSCs[25,26]. The pathways for AMPK, ERK/MAPK, PTEN and TGF-β are also implicated in HSC activation[27-30]. We noticed that a number of pathways were present in the charts for both up- and downregulated miRNAs, which could denote the complexity of regulated targets by each single miRNA, and possibly a cooperative effect between up- and downregulated miRNAs.

A number of publications have shown that miR-146a is involved in inflammatory diseases, regulation of the immune response and NF-κB[19,31-33]. In the early events of liver fibrosis, the activation of HSCs is in part driven by the hepatic inflammatory process, during which different cytokines are secreted by various liver cells, like Kupffer cells, endothelial cells and hepatocytes[34,35]. Involvement of NF-κB in HSC activation has also been shown in several research papers[36,37]. Therefore, we overexpressed miR-146a in an HSC cell line and observed changes consistent with the findings from Bhaumik et al[19]. The detected increase in the NF-κB transcript (Figure 5E) could be explained by a feedback mechanism to the reduced nuclear activity, which leads to the upregulation of the mRNA.

Cox-2 is inducible in activated HSCs by various stimuli and is thought to regulate proliferation[21]. Others have shown that the inhibition of this enzyme has a beneficial antifibrotic effect[20,38,39]. The seemingly discrepant findings of the protein (lower) and transcript (elevated) level for Cox-2 in the miR-146a-overexpressing HSCs (Figure 5D and E) hint at independent pathways for the regulation of Cox-2. These pathways have been shown for intestinal myofibroblasts[40] and during ischemic injury of ileal mucosa[41]. Lasa et al[42] and others have shown that the p38 MAPK signaling cascade is able to stabilize the Cox-2 mRNA[43], which could also explain an elevated transcript level. We also cannot exclude that other mechanisms could be involved in stabilizing the Cox-2 mRNA and/or a regulation of Cox-2 by other miRNAs like miR-26a or 143, which are also present in the cell line HSC-2 and for which Cox-2 is a predicted target.

In contrast, the IL-6 mRNA, another molecule regulated by NF-κB, was downregulated (Figure 5E). This observation implies that IL-6 regulation in HSCs is more tightly associated with NF-κB than that of Cox-2.

We were also interested to know whether downregulation of the NF-κB DNA binding activity triggered by miR-146a overexpression could facilitate a feedback loop in HSCs; a notion supported by the fact that the promoter region of miR-146a contains a number of NF-κB binding sites[18]. As expected, a reduction in the NF-κB DNA binding activity (Figure 6B) leads to a decrease in miR-146a (Figure 6C). The observed upregulation of Cox-2 protein (Figure 6D) was somewhat surprising and again substantiated the speculation that other pathways such as p38 MAPK, C-Jun N-terminal kinase and ERK could participate in the regulation of Cox-2 in HSCs[40,44,45].

The microarray analysis revealed that the transcriptome changes caused by miR-146a overexpression are complex and numerous pathways are affected (Figure 7, Supplementary Tables 1 and 2). We found that several DEGs coincided with data from earlier publications on HSC activation[24,46], suggesting that a number of genes affected by miR-146a overexpression are also involved in the activation process. Pathway analysis of the DEGs (Figure 7) confirms a link between miR-146a and inflammation (LPS/IL-1 mediated inhibition of RXR function, eicosanoid signaling, nitrogen metabolism and NRF2-mediated oxidative stress response pathways). That the miR-146a overexpression in HSC-2 cells leads to changes in the pathway called hepatic fibrosis/HSC activation emphasizes that these changes are specific for the HSCs. The upregulation of TIMP-3 (Supplementary Table 1 and Figure 8) again emphasizes the involvement of miR-146a in inflammatory processes and immunity, by linking it to the TNFα activity[47].

We noticed a robust downregulation of miR-146a during in vitro, but a missing regulation of miR-146a during in vivo activation of pHSCs (CDE diet). We hypothesized that there is a dynamic component in the regulation of miR-146a. We effectively found that there is a time-dependent regulation of miR-146a over 10 d of in vitro activation of pHSCs. From an in vivo perspective, it could be a possibility that miR-146a is decreased following the first insult to the liver, but reaches almost a normal level during the developing fibrosis, as seen for the in vivo activated pHSCs (CDE diet). The mechanism behind this miR-146a regulation is not clear, but the involvement of different transcription factors [NF-IL6, interferon regulatory factor (IRF 3/7)] binding to its promoter region is conceivable[18].

The dynamic nature of miRNA regulation during the in vitro activation of pHSCs could also partially explain the differences in the expression pattern of the miRNAs in vitro and in vivo. The dynamic nature of miRNA expression has been shown for the T-cell development[48], and it makes sense if we consider the multitude of effects a single miRNA can have due to the imperfect complementarity to its target sequence.

The in vivo targets of a miRNA treatment are pHSCs, therefore, we assessed the effects of several miRNAs mimics (miR-26a, 29a, 146a) and inhibitor (miR-214) on the activation state of pHSCs. The transfection with a combination of all mimics and inhibitor was performed so as to examine possible cooperative effects between different miRNAs, as a first step to understand the cooperativity of miRNA expression changes during HSC activation. The miR-26a, 29a mimics and miR-214 inhibitor showed a significant suppression of the ColI mRNA (Figure 9B). This is somewhat surprising because even though a number of collagens are predicted targets for miR-26a and 29a, none has a perfect binding site, which would explain regulation by mRNA degradation. Therefore, we conclude that the mechanism by which miR-26a, 29a and 214 downregulate the ColI mRNA is indirect, as also suggested by van Rooij et al[49] for miR-29a. The downregulation of ColI by the quadruple transfection shows some synergistic effect between the miRNAs.

Our findings showed the differential regulation of miRNAs in in vitro and in vivo activation of pHSCs, and particularly, the involvement of miR-26a, 29a and 214 in the regulation of ColI mRNA. Moreover, miR-146a overexpression or treatment with miR-146a mimic upregulates TIMP-3 mRNA, which suggests an association between miR-146a, TNFα activity and inflammation. In conclusion, our observations help build a global picture of the miRNA regulation during HSC activation in vitro and in vivo, and may have important implications when considering a therapeutic approach for treating liver fibrosis using miRNAs.

COMMENTS

Background

miRNAs are a relatively new and exciting tool to control the expression of multiple genes. During liver injury and subsequent wound healing involving hepatic stellate cells (HSCs), complex regulatory processes occur and have to be tightly regulated in this cell type. miRNAs could be one tool to control these processes, and therefore, it is of interest to the research community to gain information about the expression of miRNAs during liver fibrosis in HSCs.

Research frontiers

Liver fibrosis and subsequently cirrhosis are common outcomes of chronic injuries to the liver. HSCs are involved in liver fibrosis and repair. The tools for the treatment of liver fibrosis are limited and are still under development. In this study, the authors aimed to gain information for the possible role of miRNAs in liver fibrosis and whether they could become a future tool to develop a treatment for liver fibrosis by addressing the changes in HSCs.

Innovations and breakthroughs

Different publications have analyzed the miRNA expression in HSCs in vitro and studied the effect of various differentially regulated miRNAs in HSCs. The authors analyzed the miRNA expression in an in vivo model of hepatic fibrosis, namely choline-deficient ethionine supplemented diet. Furthermore, they studied the transcriptome changes upon overexpression of miR-146a and found that, in particular, tissue inhibitor of metalloproteinase-3 showed robust up-regulation, a hitherto unreported effect, which emphasizes its involvement in inflammation. Another important finding was the dynamics of miRNA regulation during the in vitro activation of HSCs.

Applications

miRNAs are becoming a promising tool for the regulation of gene expression. In order to use this tool, it is necessary to understand the role and regulation of the targeted miRNA. In this study, the authors describe the dynamic regulation of specific miRNAs. The results of this study show clearly that the use of miRNAs as target molecules will have to take this dynamic component into consideration. The same is valid for the use of miRNAs as therapeutic agents.

Terminology

miRNAs are small non-coding RNAs that are about 23 nucleotides long. The versatility of miRNAs depends on the imperfect binding (seed region) to the 3’-UTR of mRNAs. This imperfect binding results in many different binding partners. The regulation by miRNAs leads to a translational repression and/or mRNA destabilization.

Peer review

The field of miRNA research as well as HSC activation mechanisms are very up to date and important areas of research, in order to find new strategies against liver fibrosis. The methods used are comprehensive and convincing. In all, the study was fairly well conducted and interesting.

Acknowledgments

The authors would like to thank the Histopathology Unit at the Biopolis Shared Facilities for the expert hematoxylin and eosin and SMAA staining.

Footnotes

Supported by Institute of Bioengineering and Nanotechnology (Biomedical Research Council, Agency for Science, Technology and Research, Singapore)

Peer reviewers: Dr. Katja Breitkopf, Department of Medicine II, University Hospital Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany; Richard A Rippe, Professor of Medicine, Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina, Chapel Hill, NC 27599-7032, United States

S- Editor Wang JL L- Editor Kerr C E- Editor Zheng XM

References

  • 1.Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115:209–218. doi: 10.1172/JCI24282. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Gressner AM, Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med. 2006;10:76–99. doi: 10.1111/j.1582-4934.2006.tb00292.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Maher JJ, McGuire RF. Extracellular matrix gene expression increases preferentially in rat lipocytes and sinusoidal endothelial cells during hepatic fibrosis in vivo. J Clin Invest. 1990;86:1641–1648. doi: 10.1172/JCI114886. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Stefanovic B, Hellerbrand C, Holcik M, Briendl M, Aliebhaber S, Brenner DA. Posttranscriptional regulation of collagen alpha1(I) mRNA in hepatic stellate cells. Mol Cell Biol. 1997;17:5201–5209. doi: 10.1128/mcb.17.9.5201. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Mann DA, Smart DE. Transcriptional regulation of hepatic stellate cell activation. Gut. 2002;50:891–896. doi: 10.1136/gut.50.6.891. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215–233. doi: 10.1016/j.cell.2009.01.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet. 2008;9:102–114. doi: 10.1038/nrg2290. [DOI] [PubMed] [Google Scholar]
  • 8.O'Hara SP, Mott JL, Splinter PL, Gores GJ, LaRusso NF. MicroRNAs: key modulators of posttranscriptional gene expression. Gastroenterology. 2009;136:17–25. doi: 10.1053/j.gastro.2008.11.028. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Pauley KM, Cha S, Chan EK. MicroRNA in autoimmunity and autoimmune diseases. J Autoimmun. 2009;32:189–194. doi: 10.1016/j.jaut.2009.02.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Weiskirchen R, Gressner AM. Isolation and culture of hepatic stellate cells. Methods Mol Med. 2005;117:99–113. doi: 10.1385/1-59259-940-0:099. [DOI] [PubMed] [Google Scholar]
  • 11.Maubach G, Lim MC, Zhuo L. Nuclear cathepsin F regulates activation markers in rat hepatic stellate cells. Mol Biol Cell. 2008;19:4238–4248. doi: 10.1091/mbc.E08-03-0291. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30:207–210. doi: 10.1093/nar/30.1.207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Chua SW, Vijayakumar P, Nissom PM, Yam CY, Wong VV, Yang H. A novel normalization method for effective removal of systematic variation in microarray data. Nucleic Acids Res. 2006;34:e38. doi: 10.1093/nar/gkl024. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120:15–20. doi: 10.1016/j.cell.2004.12.035. [DOI] [PubMed] [Google Scholar]
  • 15.Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 2006;34:D140–D144. doi: 10.1093/nar/gkj112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Enright AJ, John B, Gaul U, Tuschl T, Sander C, Marks DS. MicroRNA targets in Drosophila. Genome Biol. 2003;5:R1. doi: 10.1186/gb-2003-5-1-r1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Lim MC, Maubach G, Zhuo L. TGF-beta1 down-regulates connexin 43 expression and gap junction intercellular communication in rat hepatic stellate cells. Eur J Cell Biol. 2009;88:719–730. doi: 10.1016/j.ejcb.2009.08.003. [DOI] [PubMed] [Google Scholar]
  • 18.Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA. 2006;103:12481–12486. doi: 10.1073/pnas.0605298103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Bhaumik D, Scott GK, Schokrpur S, Patil CK, Campisi J, Benz CC. Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells. Oncogene. 2008;27:5643–5647. doi: 10.1038/onc.2008.171. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Paik YH, Kim JK, Lee JI, Kang SH, Kim DY, An SH, Lee SJ, Lee DK, Han KH, Chon CY, et al. Celecoxib induces hepatic stellate cell apoptosis through inhibition of Akt activation and suppresses hepatic fibrosis in rats. Gut. 2009;58:1517–1527. doi: 10.1136/gut.2008.157420. [DOI] [PubMed] [Google Scholar]
  • 21.Gallois C, Habib A, Tao J, Moulin S, Maclouf J, Mallat A, Lotersztajn S. Role of NF-kappaB in the antiproliferative effect of endothelin-1 and tumor necrosis factor-alpha in human hepatic stellate cells. Involvement of cyclooxygenase-2. J Biol Chem. 1998;273:23183–23190. doi: 10.1074/jbc.273.36.23183. [DOI] [PubMed] [Google Scholar]
  • 22.Lee MH, Knäuper V, Becherer JD, Murphy G. Full-length and N-TIMP-3 display equal inhibitory activities toward TNF-alpha convertase. Biochem Biophys Res Commun. 2001;280:945–950. doi: 10.1006/bbrc.2000.4192. [DOI] [PubMed] [Google Scholar]
  • 23.Guo CJ, Pan Q, Cheng T, Jiang B, Chen GY, Li DG. Changes in microRNAs associated with hepatic stellate cell activation status identify signaling pathways. FEBS J. 2009;276:5163–5176. doi: 10.1111/j.1742-4658.2009.07213.x. [DOI] [PubMed] [Google Scholar]
  • 24.De Minicis S, Seki E, Uchinami H, Kluwe J, Zhang Y, Brenner DA, Schwabe RF. Gene expression profiles during hepatic stellate cell activation in culture and in vivo. Gastroenterology. 2007;132:1937–1946. doi: 10.1053/j.gastro.2007.02.033. [DOI] [PubMed] [Google Scholar]
  • 25.Langer DA, Das A, Semela D, Kang-Decker N, Hendrickson H, Bronk SF, Katusic ZS, Gores GJ, Shah VH. Nitric oxide promotes caspase-independent hepatic stellate cell apoptosis through the generation of reactive oxygen species. Hepatology. 2008;47:1983–1993. doi: 10.1002/hep.22285. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Svegliati-Baroni G, Saccomanno S, van Goor H, Jansen P, Benedetti A, Moshage H. Involvement of reactive oxygen species and nitric oxide radicals in activation and proliferation of rat hepatic stellate cells. Liver. 2001;21:1–12. doi: 10.1034/j.1600-0676.2001.210101.x. [DOI] [PubMed] [Google Scholar]
  • 27.Hellerbrand C, Stefanovic B, Giordano F, Burchardt ER, Brenner DA. The role of TGFbeta1 in initiating hepatic stellate cell activation in vivo. J Hepatol. 1999;30:77–87. doi: 10.1016/s0168-8278(99)80010-5. [DOI] [PubMed] [Google Scholar]
  • 28.Takashima M, Parsons CJ, Ikejima K, Watanabe S, White ES, Rippe RA. The tumor suppressor protein PTEN inhibits rat hepatic stellate cell activation. J Gastroenterol. 2009;44:847–855. doi: 10.1007/s00535-009-0073-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Caligiuri A, Bertolani C, Guerra CT, Aleffi S, Galastri S, Trappoliere M, Vizzutti F, Gelmini S, Laffi G, Pinzani M, et al. Adenosine monophosphate-activated protein kinase modulates the activated phenotype of hepatic stellate cells. Hepatology. 2008;47:668–676. doi: 10.1002/hep.21995. [DOI] [PubMed] [Google Scholar]
  • 30.Marra F, Arrighi MC, Fazi M, Caligiuri A, Pinzani M, Romanelli RG, Efsen E, Laffi G, Gentilini P. Extracellular signal-regulated kinase activation differentially regulates platelet-derived growth factor's actions in hepatic stellate cells, and is induced by in vivo liver injury in the rat. Hepatology. 1999;30:951–958. doi: 10.1002/hep.510300406. [DOI] [PubMed] [Google Scholar]
  • 31.Nakasa T, Miyaki S, Okubo A, Hashimoto M, Nishida K, Ochi M, Asahara H. Expression of microRNA-146 in rheumatoid arthritis synovial tissue. Arthritis Rheum. 2008;58:1284–1292. doi: 10.1002/art.23429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Perry MM, Moschos SA, Williams AE, Shepherd NJ, Larner-Svensson HM, Lindsay MA. Rapid changes in microRNA-146a expression negatively regulate the IL-1beta-induced inflammatory response in human lung alveolar epithelial cells. J Immunol. 2008;180:5689–5698. doi: 10.4049/jimmunol.180.8.5689. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Williams AE, Perry MM, Moschos SA, Larner-Svensson HM, Lindsay MA. Role of miRNA-146a in the regulation of the innate immune response and cancer. Biochem Soc Trans. 2008;36:1211–1215. doi: 10.1042/BST0361211. [DOI] [PubMed] [Google Scholar]
  • 34.Li JT, Liao ZX, Ping J, Xu D, Wang H. Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies. J Gastroenterol. 2008;43:419–428. doi: 10.1007/s00535-008-2180-y. [DOI] [PubMed] [Google Scholar]
  • 35.Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem. 2000;275:2247–2250. doi: 10.1074/jbc.275.4.2247. [DOI] [PubMed] [Google Scholar]
  • 36.Hellerbrand C, Jobin C, Iimuro Y, Licato L, Sartor RB, Brenner DA. Inhibition of NFkappaB in activated rat hepatic stellate cells by proteasome inhibitors and an IkappaB super-repressor. Hepatology. 1998;27:1285–1295. doi: 10.1002/hep.510270514. [DOI] [PubMed] [Google Scholar]
  • 37.Lang A, Schoonhoven R, Tuvia S, Brenner DA, Rippe RA. Nuclear factor kappaB in proliferation, activation, and apoptosis in rat hepatic stellate cells. J Hepatol. 2000;33:49–58. doi: 10.1016/s0168-8278(00)80159-2. [DOI] [PubMed] [Google Scholar]
  • 38.Cheng J, Imanishi H, Liu W, Iwasaki A, Ueki N, Nakamura H, Hada T. Inhibition of the expression of alpha-smooth muscle actin in human hepatic stellate cell line, LI90, by a selective cyclooxygenase 2 inhibitor, NS-398. Biochem Biophys Res Commun. 2002;297:1128–1134. doi: 10.1016/s0006-291x(02)02301-x. [DOI] [PubMed] [Google Scholar]
  • 39.Planagumà A, Clària J, Miquel R, López-Parra M, Titos E, Masferrer JL, Arroyo V, Rodés J. The selective cyclooxygenase-2 inhibitor SC-236 reduces liver fibrosis by mechanisms involving non-parenchymal cell apoptosis and PPARgamma activation. FASEB J. 2005;19:1120–1122. doi: 10.1096/fj.04-2753fje. [DOI] [PubMed] [Google Scholar]
  • 40.Mifflin RC, Saada JI, Di Mari JF, Adegboyega PA, Valentich JD, Powell DW. Regulation of COX-2 expression in human intestinal myofibroblasts: mechanisms of IL-1-mediated induction. Am J Physiol Cell Physiol. 2002;282:C824–C834. doi: 10.1152/ajpcell.00388.2001. [DOI] [PubMed] [Google Scholar]
  • 41.Shifflett DE, Jones SL, Moeser AJ, Blikslager AT. Mitogen-activated protein kinases regulate COX-2 and mucosal recovery in ischemic-injured porcine ileum. Am J Physiol Gastrointest Liver Physiol. 2004;286:G906–G913. doi: 10.1152/ajpgi.00478.2003. [DOI] [PubMed] [Google Scholar]
  • 42.Lasa M, Mahtani KR, Finch A, Brewer G, Saklatvala J, Clark AR. Regulation of cyclooxygenase 2 mRNA stability by the mitogen-activated protein kinase p38 signaling cascade. Mol Cell Biol. 2000;20:4265–4274. doi: 10.1128/mcb.20.12.4265-4274.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Ridley SH, Dean JL, Sarsfield SJ, Brook M, Clark AR, Saklatvala J. A p38 MAP kinase inhibitor regulates stability of interleukin-1-induced cyclooxygenase-2 mRNA. FEBS Lett. 1998;439:75–80. doi: 10.1016/s0014-5793(98)01342-8. [DOI] [PubMed] [Google Scholar]
  • 44.Guan Z, Buckman SY, Miller BW, Springer LD, Morrison AR. Interleukin-1beta-induced cyclooxygenase-2 expression requires activation of both c-Jun NH2-terminal kinase and p38 MAPK signal pathways in rat renal mesangial cells. J Biol Chem. 1998;273:28670–28676. doi: 10.1074/jbc.273.44.28670. [DOI] [PubMed] [Google Scholar]
  • 45.Guan Z, Buckman SY, Pentland AP, Templeton DJ, Morrison AR. Induction of cyclooxygenase-2 by the activated MEKK1 --> SEK1/MKK4 --> p38 mitogen-activated protein kinase pathway. J Biol Chem. 1998;273:12901–12908. doi: 10.1074/jbc.273.21.12901. [DOI] [PubMed] [Google Scholar]
  • 46.Jiang F, Parsons CJ, Stefanovic B. Gene expression profile of quiescent and activated rat hepatic stellate cells implicates Wnt signaling pathway in activation. J Hepatol. 2006;45:401–409. doi: 10.1016/j.jhep.2006.03.016. [DOI] [PubMed] [Google Scholar]
  • 47.Mohammed FF, Smookler DS, Taylor SE, Fingleton B, Kassiri Z, Sanchez OH, English JL, Matrisian LM, Au B, Yeh WC, et al. Abnormal TNF activity in Timp3-/- mice leads to chronic hepatic inflammation and failure of liver regeneration. Nat Genet. 2004;36:969–977. doi: 10.1038/ng1413. [DOI] [PubMed] [Google Scholar]
  • 48.Neilson JR, Zheng GX, Burge CB, Sharp PA. Dynamic regulation of miRNA expression in ordered stages of cellular development. Genes Dev. 2007;21:578–589. doi: 10.1101/gad.1522907. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS, Hill JA, Olson EN. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA. 2008;105:13027–13032. doi: 10.1073/pnas.0805038105. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from World Journal of Gastroenterology : WJG are provided here courtesy of Baishideng Publishing Group Inc

RESOURCES